1351
|
Hollon T, Nguyen V, Smith BW, Lewis S, Junck L, Orringer DA. Supratentorial hemispheric ependymomas: an analysis of 109 adults for survival and prognostic factors. J Neurosurg 2016; 125:410-8. [PMID: 26745489 DOI: 10.3171/2015.7.jns151187] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
OBJECTIVE Survival rates and prognostic factors for supratentorial hemispheric ependymomas have not been determined. The authors therefore designed a retrospective study to determine progression-free survival (PFS), overall survival (OS), and prognostic factors for hemispheric ependymomas. METHODS The study population consisted of 8 patients from our institution and 101 patients from the literature with disaggregated survival information (n = 109). Patient age, sex, tumor side, tumor location, extent of resection (EOR), tumor grade, postoperative chemotherapy, radiation, time to recurrence, and survival were recorded. Kaplan-Meier survival analyses and Cox proportional hazard models were completed to determine survival rates and prognostic factors. RESULTS Anaplastic histology/WHO Grade III tumors were identified in 62% of cases and correlated with older age. Three-, 5-, and 10-year PFS rates were 57%, 51%, and 42%, respectively. Three-, 5-, and 10-year OS rates were 77%, 71%, and 58%, respectively. EOR and tumor grade were identified on both Kaplan-Meier log-rank testing and univariate Cox proportional hazard models as prognostic for PFS and OS. Both EOR and tumor grade remained prognostic on multivariate analysis. Subtotal resection (STR) predicted a worse PFS (hazard ratio [HR] 4.764, p = 0.001) and OS (HR 4.216, p = 0.008). Subgroup survival analysis of patients with STR demonstrated a 5- and 10-year OS of 28% and 0%, respectively. WHO Grade III tumors also had worse PFS (HR 10.2, p = 0.004) and OS (HR 9.1, p = 0.035). Patients with WHO Grade III tumors demonstrated 5- and 10-year OS of 61% and 46%, respectively. Postoperative radiation was not prognostic for PFS or OS. CONCLUSIONS A high incidence of anaplastic histology was found in hemispheric ependymomas and was associated with older age. EOR and tumor grade were prognostic factors for PFS and OS on multivariate analysis. STR or WHO Grade III pathology, or both, predicted worse overall prognosis in patients with hemispheric ependymoma.
Collapse
Affiliation(s)
| | - Vincent Nguyen
- Temple University Medical School, Philadelphia, Pennsylvania
| | | | | | - Larry Junck
- Neurology, University of Michigan, Ann Arbor, Michigan; and
| | | |
Collapse
|
1352
|
ERKAN EP, VURGUN U, ERBAYRAKTAR RS, ERBAYRAKTAR Z. Glioblastoma stem cells: a therapeutic challenge. Turk J Biol 2016. [DOI: 10.3906/biy-1508-79] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
1353
|
Tianqin G, Chunlei C, Jingjing W. Synergistic Anti-glioma Effects in Vitro and in Vivo of Enediyne Antibiotic Neocarzinostatin and Paclitaxel via Enhanced Growth Delay and Apoptosis-Induction. Biol Pharm Bull 2016; 39:1623-1630. [DOI: 10.1248/bpb.b16-00285] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
1354
|
Abstract
More than 250,000 new cases of primary malignant brain tumors are diagnosed annually worldwide, 77% of which are gliomas. A small proportion of gliomas are caused by the inheritance of rare high-penetrance genetic variants or high-dose radiation. Since 2009, inherited genetic variants in 10 regions near eight different genes have been consistently associated with glioma risk via genome-wide association studies. Most of these variants increase glioma risk by 20-40%, but two have higher relative risks. One on chromosome 8 increases risk of IDH-mutated gliomas sixfold and another that affects TP53 function confers a 2.5-fold increased risk of glioma. Functions of some of the other risk variants are known or suspected, but future research will determine functions of other risk loci. Recent progress also has been made in defining subgroups of glioma based on acquired alterations within tumors. Allergy history has been consistently associated with reduced glioma risk, though the mechanisms have not yet been clarified. Future studies will need to be large enough so that environmental and constitutive genetic risk factors can be examined within molecularly defined, etiologically homogeneous subgroups.
Collapse
Affiliation(s)
- Kyle M Walsh
- Division of Neuroepidemiology, Department of Neurological Surgery, University of California San Francisco and UCSF Helen Diller Family Cancer Center, San Francisco, CA, USA
| | - Hiroko Ohgaki
- Section of Molecular Pathology, International Agency for Research on Cancer, Lyon, France
| | - Margaret R Wrensch
- Division of Neuroepidemiology, Department of Neurological Surgery, University of California San Francisco and UCSF Helen Diller Family Cancer Center, San Francisco, CA, USA.
| |
Collapse
|
1355
|
Berger MS, Hervey-Jumper S, Wick W. Astrocytic gliomas WHO grades II and III. HANDBOOK OF CLINICAL NEUROLOGY 2016; 134:345-60. [PMID: 26948365 DOI: 10.1016/b978-0-12-802997-8.00021-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
World Health Organization grades II and III lower-grade astrocytomas are a challenging area in neuro-oncology. One the one hand, for proper diagnosis, the analysis of molecular factors, especially mutation status of isocitrate dehydrogenase and 1p/19q status in the tumor status needs to be done in addition to classical neuropathology. Further, the high clinical and prognostic value of a maximal safe resection requires a profound knowledge of presurgical diagnosis and surgical as well as imaging techniques to ensure optimal outcome for patients. Also medical treatment may be more intensive than previously believed, with randomized trials providing evidence for a benefit in overall survival by combined chemoradiation versus radiation alone. A critical problem concerns the considerable undesirable effects of therapeutic interventions on long-term health-related quality of life, cognitive and functional outcome as well as future developments in this still difficult disease that will need to be addressed in future trials.
Collapse
Affiliation(s)
- Mitchel S Berger
- Department of Neurological Surgery, University of California, San Francisco, CA, USA.
| | - Shawn Hervey-Jumper
- Department of Neurological Surgery, Taubman Health Center, Ann Arbor, MI, USA
| | - Wolfgang Wick
- Department of Neurooncology, University Clinic of Heidelberg, Heidelberg, Germany
| |
Collapse
|
1356
|
Abstract
Glioblastoma is the most common and aggressive primary brain tumor in adults. Defining histopathologic features are necrosis and endothelial proliferation, resulting in the assignment of grade IV, the highest grade in the World Health Organization (WHO) classification of brain tumors. The classic clinical term "secondary glioblastoma" refers to a minority of glioblastomas that evolve from previously diagnosed WHO grade II or grade III gliomas. Specific point mutations of the genes encoding isocitrate dehydrogenase (IDH) 1 or 2 appear to define molecularly these tumors that are associated with younger age and more favorable outcome; the vast majority of glioblastomas are IDH wild-type. Typical molecular changes in glioblastoma include mutations in genes regulating receptor tyrosine kinase (RTK)/rat sarcoma (RAS)/phosphoinositide 3-kinase (PI3K), p53, and retinoblastoma protein (RB) signaling. Standard treatment of glioblastoma includes surgery, radiotherapy, and alkylating chemotherapy. Promoter methylation of the gene encoding the DNA repair protein, O(6)-methylguanyl DNA methyltransferase (MGMT), predicts benefit from alkylating chemotherapy with temozolomide and guides choice of first-line treatment in elderly patients. Current developments focus on targeting the molecular characteristics that drive the malignant phenotype, including altered signal transduction and angiogenesis, and more recently, various approaches of immunotherapy.
Collapse
|
1357
|
Let-7a suppresses glioma cell proliferation and invasion through TGF-β/Smad3 signaling pathway by targeting HMGA2. Tumour Biol 2015; 37:8107-19. [PMID: 26715270 DOI: 10.1007/s13277-015-4674-6] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2015] [Accepted: 12/16/2015] [Indexed: 12/17/2022] Open
Abstract
It has been shown that let-7a was associated with the tumorigenesis of glioma. Our study was designed to infer how let-7a targets high-mobility AT-hook 2 (HMGA2) and suppresses glioma cell proliferation, invasion, and migration. Glioma tissues from 60 glioma patients and 10 normal brain tissues were collected in this study. Real-time quantitative reverse transcription-PCR (qRT-PCR) and in situ hybridization were used to detect the expression levels of let-7a in tissues and cells. The HMGA2 and the proteins related to transforming growth factor-beta (TGF-β)/Smad3 signaling pathway were measured by immunohistochemistry and western blot. Glioma U87 cells were transfected with either let-7a mimics, HMGA2 small interfering RNA (siRNA), let-7a mimics + HMGA2, HMGA2, or scramble. A cell counting kit-8 (CCK-8) assay was used to detect and compare the difference among various transfection groups. Glioma tumor xenograft models on mice were built to evaluate the effects of let-7a and HMGA2 siRNA on glioma tumors in vivo. The expression level of let-7a significantly downregulated in glioma tissues, while the HMGA2 positive expression rate notably increased compared with those in normal brain tissues (all P < 0.05). Moreover, the expression levels of let-7a and HMGA2 were correlated with glioma grades (all P < 0.05). The proliferation of U87 cells transfected with let-7a mimics or HMGA2 siRNA was significantly inhibited in comparison to the blank control group and the apoptosis rates of U87 cells transfected with let-7a mimics or HMGA2 siRNA were significantly higher than those in the blank control group (all P < 0.05). Let-7a or HMGA2 siRNA could remarkably attenuate the invasion and migration ability of glioma cells (all P < 0.05). Apart from that, over-expressed exogenous HMGA2 could reverse the inhibition of glioma cell metastasis and proliferation induced by let-7a. As suggested by immunohistochemistry and western blot, the expression levels of TGF-β1 and p-Smad3 significantly decreased compared with the blank or scramble group (all P < 0.05). Thus, let-7a and HMGA2 siRNA could effectively suppress the growth of tumors in glioma xenograft models. Let-7a may suppress the proliferation and invasion of glioma cells through mediating TGF-β/Smad3 signaling pathway by targeting HMGA2.
Collapse
|
1358
|
Liu Q, Cao P. Clinical and prognostic significance of HIF-1α in glioma patients: a meta-analysis. Int J Clin Exp Med 2015; 8:22073-22083. [PMID: 26885182 PMCID: PMC4729968] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2015] [Accepted: 11/19/2015] [Indexed: 06/05/2023]
Abstract
Gliomas are the most common brain tumors, leading to significant cancer-related mortality worldwide. Hypoxia-inducible factor 1-alpha (HIF-1α) was shown to be involved in the pathophysiology and management of glioma, and might offer a therapeutic target. However, the results remain inconclusive. The purpose of this study was to systematically investigate the clinical and prognostic significance of HIF-1α expression in patients with glioma. Relevant studies published between 2000 and 2015 were searched in the electronic databases. The odds ratio (OR), risk ratio (RR) and mean difference (MD) with their 95% confidence intervals (CI) were employed to calculate the strength of significance. Finally, a total of 24 articles were retrieved, including 1422 glioma patients. No significant heterogeneity was presented between studies (I(2)<50%, P>0.01). Overall, our results showed that HIF-1α expression was significantly associated with high WHO grade (III+IV) of glioma (OR=8.59, 95% CI=6.56-11.24, P<0.00001). This significant relationship was also found between HIF-1α expression and microvascular density (MD=26.32, 95% CI=14.48-38.16, P<0.0001), overall survival (OS) (3-year OS: RR=0.48, 95% CI=0.35-0.66, P<0.00001; 2-year OS: RR=0.53, 95% CI=0.38-0.73, P<0.0001; 1-year OS: RR=0.79, 95% CI=0.66-0.95, P=0.01), and the cumulative survival time. However, HIF-1α expression was not associated with age and gender of glioma patients (P>0.05). In conclusions, our results suggested that HIF-1α expression was associated with high grade of glioma and OS, indicating that HIF-1α could predict prognosis and provide clinical insights into the therapeutic strategy for patients with glioma. More studies concerning other populations are also needed in the future research.
Collapse
Affiliation(s)
- Qi Liu
- Department of Weifang People's Hospital of Brain Hospital Neurosurgery Weifang, Shangdong Province, China
| | - Peicheng Cao
- Department of Weifang People's Hospital of Brain Hospital Neurosurgery Weifang, Shangdong Province, China
| |
Collapse
|
1359
|
Quantifying the heritability of glioma using genome-wide complex trait analysis. Sci Rep 2015; 5:17267. [PMID: 26625949 PMCID: PMC4667278 DOI: 10.1038/srep17267] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2015] [Accepted: 10/07/2015] [Indexed: 12/31/2022] Open
Abstract
Genome-wide association studies (GWAS) have successfully identified a number of common single-nucleotide polymorphisms (SNPs) influencing glioma risk. While these SNPs only explain a small proportion of the genetic risk it is unclear how much is left to be detected by other, yet to be identified, common SNPs. Therefore, we applied Genome-Wide Complex Trait Analysis (GCTA) to three GWAS datasets totalling 3,373 cases and 4,571 controls and performed a meta-analysis to estimate the heritability of glioma. Our results identify heritability estimates of 25% (95% CI: 20-31%, P = 1.15 × 10(-17)) for all forms of glioma - 26% (95% CI: 17-35%, P = 1.05 × 10(-8)) for glioblastoma multiforme (GBM) and 25% (95% CI: 17-32%, P = 1.26 × 10(-10)) for non-GBM tumors. This is a substantial increase from the genetic variance identified by the currently identified GWAS risk loci (~6% of common heritability), indicating that most of the heritable risk attributable to common genetic variants remains to be identified.
Collapse
|
1360
|
Correlation of diffusion tensor and dynamic susceptibility contrast MRI with DNA ploidy and cell cycle analysis of gliomas. Clin Neurol Neurosurg 2015; 139:119-24. [DOI: 10.1016/j.clineuro.2015.09.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2015] [Revised: 08/25/2015] [Accepted: 09/22/2015] [Indexed: 01/06/2023]
|
1361
|
Lapointe S, Florescu M, Nguyen DK, Djeffal C, Bélanger K. Prophylactic anticonvulsants for gliomas: a seven-year retrospective analysis. Neurooncol Pract 2015; 2:192-198. [PMID: 31386083 DOI: 10.1093/nop/npv018] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2015] [Indexed: 11/14/2022] Open
Abstract
Background The American Academy of Neurology (AAN) does not recommend routine use of prophylactic antiepileptic drugs (pAEDs) in patients with newly diagnosed brain tumors. If used in the perioperative setting, discontinuation is suggested after the first postoperative week. It is unclear whether such recommendations are followed. Our objective was to compare our perioperative and long-term pAED use in glioma patients with AAN practice parameters. Methods Retrospective chart review was performed on 578 glioma patients from 2006 to 2013. Seizures and AED use were assessed at surgery, 3 months postoperatively and death, last visit or 16 months postoperatively. Patients were divided into three groups at surgery: seizure-free with pAED, seizure-free without pAED, and seizure patients. Long-term pAED use was defined as continued use at 3 months postsurgery without seizures. pAEDs efficacy, factors influencing its use, and survival were examined. Results Out of 578 patients identified, 330 (57.1%) were seizure-naïve preoperatively. There were no significant differences in age, histology, tumor location or resection status between seizure-free populations with and without prophylaxis. Of 330 seizure-naïve patients, 205 (62.1%) received pAEDs at surgery. Ninety-six (46.9%) of those patients were still on pAEDs 3 months postsurgery (median use = 58 days). Rate of long-term prophylaxis use decreased by 13.5% over 6 years (70.3% in 2006; 56.8% in 2012). Phenytoin was preferred in 2006 (98.2%) with increasing use of levetiracetam over 6 years (44.6% in 2012). The only predictive factor for pAED use was complete resection (P = .0069). First seizure prevalence was similar in both seizure-free populations (P = .91). The seizure population had more men (P = .007), younger patients (P < .0001), lower-grade gliomas (P = .0003) and survived longer (P = .001) compared with seizure-free populations. Conclusions In our center, long-term prophylactic AED use is high, deviating from current AAN Guidelines. Corrective measures are warranted.
Collapse
Affiliation(s)
- Sarah Lapointe
- Neurology Division, CHUM Notre-Dame Hospital, University of Montreal, 1560 Sherbrooke East, Montreal, CanadaH2L 4M1 (S.L., D.K.N.); Hematology and Oncology Department, CHUM Notre-Dame Hospital, University of Montreal, 1560 Sherbrooke East, Montreal, CanadaH2L 4M1 (M.F., C.D., K.B.)
| | - Marie Florescu
- Neurology Division, CHUM Notre-Dame Hospital, University of Montreal, 1560 Sherbrooke East, Montreal, CanadaH2L 4M1 (S.L., D.K.N.); Hematology and Oncology Department, CHUM Notre-Dame Hospital, University of Montreal, 1560 Sherbrooke East, Montreal, CanadaH2L 4M1 (M.F., C.D., K.B.)
| | - Dang K Nguyen
- Neurology Division, CHUM Notre-Dame Hospital, University of Montreal, 1560 Sherbrooke East, Montreal, CanadaH2L 4M1 (S.L., D.K.N.); Hematology and Oncology Department, CHUM Notre-Dame Hospital, University of Montreal, 1560 Sherbrooke East, Montreal, CanadaH2L 4M1 (M.F., C.D., K.B.)
| | - Chanez Djeffal
- Neurology Division, CHUM Notre-Dame Hospital, University of Montreal, 1560 Sherbrooke East, Montreal, CanadaH2L 4M1 (S.L., D.K.N.); Hematology and Oncology Department, CHUM Notre-Dame Hospital, University of Montreal, 1560 Sherbrooke East, Montreal, CanadaH2L 4M1 (M.F., C.D., K.B.)
| | - Karl Bélanger
- Neurology Division, CHUM Notre-Dame Hospital, University of Montreal, 1560 Sherbrooke East, Montreal, CanadaH2L 4M1 (S.L., D.K.N.); Hematology and Oncology Department, CHUM Notre-Dame Hospital, University of Montreal, 1560 Sherbrooke East, Montreal, CanadaH2L 4M1 (M.F., C.D., K.B.)
| |
Collapse
|
1362
|
Henker C, Kriesen T, Fürst K, Goody D, Glass Ä, Pützer BM, Piek J. Effect of 10 different polymorphisms on preoperative volumetric characteristics of glioblastoma multiforme. J Neurooncol 2015; 126:585-92. [PMID: 26603163 DOI: 10.1007/s11060-015-2005-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2015] [Accepted: 11/19/2015] [Indexed: 01/09/2023]
Abstract
There is a distinct diversity between the appearance of every glioblastoma multiforme (GBM) on pretreatment magnetic resonance imaging (MRI) with a potential impact on clinical outcome and survival of the patients. The object of this study was to determine the impact of 10 different single nucleotide polymorphisms (SNPs) on various volumetric parameters in patients harboring a GBM. We prospectively analyzed 20 steroid-naïve adult patients who had been treated for newly diagnosed GBM. The volumetry was performed using MRI with the help of a semiautomated quantitative software measuring contrast enhancing tumor volume including necrosis, central necrosis alone and peritumoral edema (PTE). We calculated ratios between the tumor volume and edema (ETR), respectively necrosis (NTR). SNP analysis was done using genomic DNA extracted from peripheral blood genotyped via PCR and sequencing. There was a strong correlation between tumor volume and PTE (p < 0.001), necrosis (p < 0.001) and NTR (p = 0.003). Age and sex had no influence on volumetric data. The Aquaporin 4-31G > A SNP had a significant influence on the ETR (p = 0.042) by decreasing the measured edema compared with the tumor volume. The Interleukin 8-251A > T SNP was significantly correlated with an increased tumor (p = 0.048), PTE (p = 0.033) and necrosis volume (p = 0.028). We found two SNPs with a distinct impact on pretreatment tumor characteristics, presenting a potential explanation for the individual diversity of GBM appearance on MRI and influence on survival.
Collapse
Affiliation(s)
- Christian Henker
- Department of Neurosurgery, University Hospital Rostock, Schillingallee 35, 18057, Rostock, Germany.
| | - Thomas Kriesen
- Department of Neurosurgery, University Hospital Rostock, Schillingallee 35, 18057, Rostock, Germany
| | - Katharina Fürst
- Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, Schillingallee 69, 18057, Rostock, Germany
| | - Deborah Goody
- Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, Schillingallee 69, 18057, Rostock, Germany
| | - Änne Glass
- Institute for Biostatistics and Informatics in Medicine, Rostock University Medical Center, Ernst-Heydemann-Str. 8, 18057, Rostock, Germany
| | - Brigitte M Pützer
- Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, Schillingallee 69, 18057, Rostock, Germany
| | - Jürgen Piek
- Department of Neurosurgery, University Hospital Rostock, Schillingallee 35, 18057, Rostock, Germany
| |
Collapse
|
1363
|
Wait SD, Prabhu RS, Burri SH, Atkins TG, Asher AL. Polymeric drug delivery for the treatment of glioblastoma. Neuro Oncol 2015; 17 Suppl 2:ii9-ii23. [PMID: 25746091 DOI: 10.1093/neuonc/nou360] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Glioblastoma (GBM) remains an almost universally fatal diagnosis. The current therapeutic mainstay consists of maximal safe surgical resection followed by radiation therapy (RT) with concomitant temozolomide (TMZ), followed by monthly TMZ (the "Stupp regimen"). Several chemotherapeutic agents have been shown to have modest efficacy in the treatment of high-grade glioma (HGG), but blood-brain barrier impermeability remains a major delivery obstacle. Polymeric drug-delivery systems, developed to allow controlled local release of biologically active substances for a variety of conditions, can achieve high local concentrations of active agents while limiting systemic toxicities. Polymerically delivered carmustine (BCNU) wafers, placed on the surface of the tumor-resection cavity, can potentially provide immediate chemotherapy to residual tumor cells during the standard delay between surgery and chemoradiotherapy. BCNU wafer implantation as monochemotherapy (with RT) in newly diagnosed HGG has been investigated in 2 phase III studies that reported significant increases in median overall survival. A number of studies have investigated the tumoricidal synergies of combination chemotherapy with BCNU wafers in newly diagnosed or recurrent HGG, and a primary research focus has been the integration of BCNU wafers into multimodality therapy with the standard Stupp regimen. Overall, the results of these studies have been encouraging in terms of safety and efficacy. However, the data must be qualified by the nature of the studies conducted. Currently, there are no phase III studies of BCNU wafers with the standard Stupp regimen. We review the rationale, biochemistry, pharmacokinetics, and research history (including toxicity profile) of this modality.
Collapse
Affiliation(s)
- Scott D Wait
- Carolina Neurosurgery and Spine Associates, Charlotte, North Carolina (S.D.W., A.L.A.); Levine Children's Hospital, Carolinas Medical Center, Charlotte, North Carolina (S.D.W.); Department of Neurosurgery, Levine Cancer Institute, and Neuroscience Institute, Carolinas Medical Center, Charlotte, North Carolina (S.D.W., T.G.A., A.L.A.); Southeast Radiation Oncology, Charlotte, North Carolina (R.S.P., S.H.B.); Department of Radiation Oncology, Levine Cancer Institute, Carolinas Medical Center, Charlotte, North Carolina (R.S.P., S.H.B.)
| | - Roshan S Prabhu
- Carolina Neurosurgery and Spine Associates, Charlotte, North Carolina (S.D.W., A.L.A.); Levine Children's Hospital, Carolinas Medical Center, Charlotte, North Carolina (S.D.W.); Department of Neurosurgery, Levine Cancer Institute, and Neuroscience Institute, Carolinas Medical Center, Charlotte, North Carolina (S.D.W., T.G.A., A.L.A.); Southeast Radiation Oncology, Charlotte, North Carolina (R.S.P., S.H.B.); Department of Radiation Oncology, Levine Cancer Institute, Carolinas Medical Center, Charlotte, North Carolina (R.S.P., S.H.B.)
| | - Stuart H Burri
- Carolina Neurosurgery and Spine Associates, Charlotte, North Carolina (S.D.W., A.L.A.); Levine Children's Hospital, Carolinas Medical Center, Charlotte, North Carolina (S.D.W.); Department of Neurosurgery, Levine Cancer Institute, and Neuroscience Institute, Carolinas Medical Center, Charlotte, North Carolina (S.D.W., T.G.A., A.L.A.); Southeast Radiation Oncology, Charlotte, North Carolina (R.S.P., S.H.B.); Department of Radiation Oncology, Levine Cancer Institute, Carolinas Medical Center, Charlotte, North Carolina (R.S.P., S.H.B.)
| | - Tyler G Atkins
- Carolina Neurosurgery and Spine Associates, Charlotte, North Carolina (S.D.W., A.L.A.); Levine Children's Hospital, Carolinas Medical Center, Charlotte, North Carolina (S.D.W.); Department of Neurosurgery, Levine Cancer Institute, and Neuroscience Institute, Carolinas Medical Center, Charlotte, North Carolina (S.D.W., T.G.A., A.L.A.); Southeast Radiation Oncology, Charlotte, North Carolina (R.S.P., S.H.B.); Department of Radiation Oncology, Levine Cancer Institute, Carolinas Medical Center, Charlotte, North Carolina (R.S.P., S.H.B.)
| | - Anthony L Asher
- Carolina Neurosurgery and Spine Associates, Charlotte, North Carolina (S.D.W., A.L.A.); Levine Children's Hospital, Carolinas Medical Center, Charlotte, North Carolina (S.D.W.); Department of Neurosurgery, Levine Cancer Institute, and Neuroscience Institute, Carolinas Medical Center, Charlotte, North Carolina (S.D.W., T.G.A., A.L.A.); Southeast Radiation Oncology, Charlotte, North Carolina (R.S.P., S.H.B.); Department of Radiation Oncology, Levine Cancer Institute, Carolinas Medical Center, Charlotte, North Carolina (R.S.P., S.H.B.)
| |
Collapse
|
1364
|
Meulepas JM, Ronckers CM, Merks J, Weijerman ME, Lubin JH, Hauptmann M. Confounding of the Association between Radiation Exposure from CT Scans and Risk of Leukemia and Brain Tumors by Cancer Susceptibility Syndromes. Cancer Epidemiol Biomarkers Prev 2015; 25:114-26. [DOI: 10.1158/1055-9965.epi-15-0636] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2015] [Accepted: 10/23/2015] [Indexed: 11/16/2022] Open
|
1365
|
Rios Velazquez E, Meier R, Dunn Jr WD, Alexander B, Wiest R, Bauer S, Gutman DA, Reyes M, Aerts HJ. Fully automatic GBM segmentation in the TCGA-GBM dataset: Prognosis and correlation with VASARI features. Sci Rep 2015; 5:16822. [PMID: 26576732 PMCID: PMC4649540 DOI: 10.1038/srep16822] [Citation(s) in RCA: 68] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2014] [Accepted: 10/20/2015] [Indexed: 01/22/2023] Open
Abstract
Reproducible definition and quantification of imaging biomarkers is essential. We evaluated a fully automatic MR-based segmentation method by comparing it to manually defined sub-volumes by experienced radiologists in the TCGA-GBM dataset, in terms of sub-volume prognosis and association with VASARI features. MRI sets of 109 GBM patients were downloaded from the Cancer Imaging archive. GBM sub-compartments were defined manually and automatically using the Brain Tumor Image Analysis (BraTumIA). Spearman's correlation was used to evaluate the agreement with VASARI features. Prognostic significance was assessed using the C-index. Auto-segmented sub-volumes showed moderate to high agreement with manually delineated volumes (range (r): 0.4 - 0.86). Also, the auto and manual volumes showed similar correlation with VASARI features (auto r = 0.35, 0.43 and 0.36; manual r = 0.17, 0.67, 0.41, for contrast-enhancing, necrosis and edema, respectively). The auto-segmented contrast-enhancing volume and post-contrast abnormal volume showed the highest AUC (0.66, CI: 0.55-0.77 and 0.65, CI: 0.54-0.76), comparable to manually defined volumes (0.64, CI: 0.53-0.75 and 0.63, CI: 0.52-0.74, respectively). BraTumIA and manual tumor sub-compartments showed comparable performance in terms of prognosis and correlation with VASARI features. This method can enable more reproducible definition and quantification of imaging based biomarkers and has potential in high-throughput medical imaging research.
Collapse
Affiliation(s)
- Emmanuel Rios Velazquez
- Departments of Radiation Oncology and Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
| | - Raphael Meier
- Institute for Surgical Technology and Biomechanics , University of Bern, Switzerland
| | - William D. Dunn Jr
- Department of Biomedical Informatics, Emory University School of Medicine, Atlanta, GA, USA
| | - Brian Alexander
- Departments of Radiation Oncology and Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
| | - Roland Wiest
- Support Center for Advanced Neuroimaging (SCAN), Institute for Diagnostic and Interventional Neuroradiology, University Hospital Inselspital and University of Bern, Bern, Switzerland
| | - Stefan Bauer
- Institute for Surgical Technology and Biomechanics , University of Bern, Switzerland
- Support Center for Advanced Neuroimaging (SCAN), Institute for Diagnostic and Interventional Neuroradiology, University Hospital Inselspital and University of Bern, Bern, Switzerland
| | - David A. Gutman
- Department of Biomedical Informatics, Emory University School of Medicine, Atlanta, GA, USA
| | - Mauricio Reyes
- Institute for Surgical Technology and Biomechanics , University of Bern, Switzerland
| | - Hugo J.W.L. Aerts
- Departments of Radiation Oncology and Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
- Departments of Radiology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
- Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA
| |
Collapse
|
1366
|
Miladinovic T, Nashed MG, Singh G. Overview of Glutamatergic Dysregulation in Central Pathologies. Biomolecules 2015; 5:3112-41. [PMID: 26569330 PMCID: PMC4693272 DOI: 10.3390/biom5043112] [Citation(s) in RCA: 75] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2015] [Revised: 11/03/2015] [Accepted: 11/05/2015] [Indexed: 12/27/2022] Open
Abstract
As the major excitatory neurotransmitter in the mammalian central nervous system, glutamate plays a key role in many central pathologies, including gliomas, psychiatric, neurodevelopmental, and neurodegenerative disorders. Post-mortem and serological studies have implicated glutamatergic dysregulation in these pathologies, and pharmacological modulation of glutamate receptors and transporters has provided further validation for the involvement of glutamate. Furthermore, efforts from genetic, in vitro, and animal studies are actively elucidating the specific glutamatergic mechanisms that contribute to the aetiology of central pathologies. However, details regarding specific mechanisms remain sparse and progress in effectively modulating glutamate to alleviate symptoms or inhibit disease states has been relatively slow. In this report, we review what is currently known about glutamate signalling in central pathologies. We also discuss glutamate's mediating role in comorbidities, specifically cancer-induced bone pain and depression.
Collapse
Affiliation(s)
- Tanya Miladinovic
- Department of Pathology and Molecular Medicine, McMaster University, 1280 Main Street West, Hamilton, ON L8S 4L8, Canada.
| | - Mina G Nashed
- Department of Pathology and Molecular Medicine, McMaster University, 1280 Main Street West, Hamilton, ON L8S 4L8, Canada.
| | - Gurmit Singh
- Department of Pathology and Molecular Medicine, McMaster University, 1280 Main Street West, Hamilton, ON L8S 4L8, Canada.
| |
Collapse
|
1367
|
Presence of neural progenitors in spontaneous canine gliomas: A histopathological and immunohistochemical study of 20 cases. Vet J 2015; 209:125-32. [PMID: 26831167 DOI: 10.1016/j.tvjl.2015.10.039] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2014] [Revised: 10/13/2015] [Accepted: 10/13/2015] [Indexed: 12/13/2022]
Abstract
Gliomas are the most common primary brain tumours in humans and are associated with a poor prognosis. An accurate animal model of human glioma tumorigenesis is needed to test new treatment strategies. Dogs represent a promising model because they develop spontaneous diffusely-infiltrating gliomas. This study investigated whether spontaneous canine gliomas contain cancer stem cells previously identified in all grades of human gliomas. Twenty spontaneous cases of canine gliomas were graded according to the human WHO classification. The expression of different markers of lineage differentiation was evaluated with immunohistochemistry as follows: nestin and CD133 for neural stem cells, doublecortin for neuronal progenitor cells, Olig2 for glial progenitor cells, glial fibrillary acidic protein, vimentin and S-100 for mature glial cells, and NeuN and βIII-tubulin for mature neurons. Gliomas were characterised as follows: five grade II (oligodendrogliomas); nine grade III (seven anaplastic oligodendrogliomas, one anaplastic astrocytoma, one anaplastic oligoastrocytoma); six grade IV (glioblastomas). Immunohistochemical evaluation revealed that (1) nestin and CD133 were expressed in all grades of gliomas with a higher proportion of positive cells in high-grade gliomas; (2) the expression of S-100 protein and Olig2 did not differ substantially between astrocytic and oligodendroglial tumours, and (3) all gliomas were negative for mature neuron markers. The results demonstrated the presence of undifferentiated neural progenitors in all grades of spontaneous canine gliomas, confirming the relevance of this animal model for further studies on cancer stem cells.
Collapse
|
1368
|
Ertosun MG, Rubin DL. Automated Grading of Gliomas using Deep Learning in Digital Pathology Images: A modular approach with ensemble of convolutional neural networks. AMIA ... ANNUAL SYMPOSIUM PROCEEDINGS. AMIA SYMPOSIUM 2015; 2015:1899-1908. [PMID: 26958289 PMCID: PMC4765616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Brain glioma is the most common primary malignant brain tumors in adults with different pathologic subtypes: Lower Grade Glioma (LGG) Grade II, Lower Grade Glioma (LGG) Grade III, and Glioblastoma Multiforme (GBM) Grade IV. The survival and treatment options are highly dependent of this glioma grade. We propose a deep learning-based, modular classification pipeline for automated grading of gliomas using digital pathology images. Whole tissue digitized images of pathology slides obtained from The Cancer Genome Atlas (TCGA) were used to train our deep learning modules. Our modular pipeline provides diagnostic quality statistics, such as precision, sensitivity and specificity, of the individual deep learning modules, and (1) facilitates training given the limited data in this domain, (2) enables exploration of different deep learning structures for each module, (3) leads to developing less complex modules that are simpler to analyze, and (4) provides flexibility, permitting use of single modules within the framework or use of other modeling or machine learning applications, such as probabilistic graphical models or support vector machines. Our modular approach helps us meet the requirements of minimum accuracy levels that are demanded by the context of different decision points within a multi-class classification scheme. Convolutional Neural Networks are trained for each module for each sub-task with more than 90% classification accuracies on validation data set, and achieved classification accuracy of 96% for the task of GBM vs LGG classification, 71% for further identifying the grade of LGG into Grade II or Grade III on independent data set coming from new patients from the multi-institutional repository.
Collapse
Affiliation(s)
| | - Daniel L Rubin
- Department of Radiology, Stanford University, Stanford, CA, USA; Department of Medicine (Biomedical Informatics Research), Stanford University, Stanford, CA, USA
| |
Collapse
|
1369
|
Lehrer S, Green S, Rendo A, Rosenzweig KE. Measles may be a Risk Factor for Malignant Brain Tumors. Brain Tumor Res Treat 2015; 3:65-7. [PMID: 26605259 PMCID: PMC4642282 DOI: 10.14791/btrt.2015.3.2.65] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2014] [Revised: 01/16/2015] [Accepted: 10/01/2015] [Indexed: 11/20/2022] Open
Abstract
Background A possible risk factor for brain tumor might be measles, since late neurologic sequelae are part of measles pathology. Subacute sclerosing panencephalitis, a devastating neurologic illness, is prone to develop years after measles infection. Methods Because measles damage to the brain might increase the risk of brain tumor, we examined the relationship of measles incidence in 1960 and brain tumor incidence in 50 US States and the District of Columbia, 2004-2007. Data on number of cases of measles by state in 1960 are from the Morbidity and Mortality Weekly Report. In 1960 measles was a childhood illness. We calculated measles incidence by obtaining the population of each state from the 1960 US Census and then age adjusting our results to the cumulative percent of the state population under age 21, since this would have been the measles-infected group. Data on the percentage white population by state are from the US Census (www.census.gov). Age-adjusted incidence (to the 2000 US standard population) of brain tumors is from the Central Brain Tumor Registry of the United States 2011 report. Results There was a significant correlation between 1960 measles incidence and incidence of malignant brain tumors in persons 20 and older in 2004-2007 (r=0.321, p=0.026). Because glioblastoma is more frequent in whites and males, multivariate linear regression was performed with tumor incidence as the dependent variable, measles incidence, percent white population, and sex ratio by state as independent variables. Measles incidence was significantly correlated with malignant brain tumor incidence (β=0.361, p<0.001) and independent of the effect of race (β=0.734, p<0.001) and sex ratio m/f (β=-0.478, p<0.001). There was no correlation of measles incidence with brain tumor incidence in persons younger than 20. Conclusion Inflammation is a critical component of tumor development. The inflammation of measles-induced subacute sclerosing panencephalitis, even subclinical cases, could well promote tumor formation, since many tumors arise from sites of infection, chronic irritation and inflammation.
Collapse
Affiliation(s)
- Steven Lehrer
- Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Sheryl Green
- Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Angela Rendo
- Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Kenneth E Rosenzweig
- Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| |
Collapse
|
1370
|
Coburger J, Merkel A, Scherer M, Schwartz F, Gessler F, Roder C, Pala A, König R, Bullinger L, Nagel G, Jungk C, Bisdas S, Nabavi A, Ganslandt O, Seifert V, Tatagiba M, Senft C, Mehdorn M, Unterberg AW, Rössler K, Wirtz CR. Low-grade Glioma Surgery in Intraoperative Magnetic Resonance Imaging. Neurosurgery 2015; 78:775-86. [DOI: 10.1227/neu.0000000000001081] [Citation(s) in RCA: 91] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Abstract
BACKGROUND:
The ideal treatment strategy for low-grade gliomas (LGGs) is a controversial topic. Additionally, only smaller single-center series dealing with the concept of intraoperative magnetic resonance imaging (iMRI) have been published.
OBJECTIVE:
To investigate determinants for patient outcome and progression-free-survival (PFS) after iMRI-guided surgery for LGGs in a multicenter retrospective study initiated by the German Study Group for Intraoperative Magnetic Resonance Imaging.
METHODS:
A retrospective consecutive assessment of patients treated for LGGs (World Health Organization grade II) with iMRI-guided resection at 6 neurosurgical centers was performed. Eloquent location, extent of resection, first-line adjuvant treatment, neurophysiological monitoring, awake brain surgery, intraoperative ultrasound, and field-strength of iMRI were analyzed, as well as progression-free survival (PFS), new permanent neurological deficits, and complications. Multivariate binary logistic and Cox regression models were calculated to evaluate determinants of PFS, gross total resection (GTR), and adjuvant treatment.
RESULTS:
A total of 288 patients met the inclusion criteria. On multivariate analysis, GTR significantly increased PFS (hazard ratio, 0.44; P < .01), whereas “failed” GTR did not differ significantly from intended subtotal-resection. Combined radiochemotherapy as adjuvant therapy was a negative prognostic factor (hazard ratio: 2.84, P < .01). Field strength of iMRI was not associated with PFS. In the binary logistic regression model, use of high-field iMRI (odds ratio: 0.51, P < .01) was positively and eloquent location (odds ratio: 1.99, P < .01) was negatively associated with GTR. GTR was not associated with increased rates of new permanent neurological deficits.
CONCLUSION:
GTR was an independent positive prognostic factor for PFS in LGG surgery. Patients with accidentally left tumor remnants showed a similar prognosis compared with patients harboring only partially resectable tumors. Use of high-field iMRI was significantly associated with GTR. However, the field strength of iMRI did not affect PFS.
Collapse
Affiliation(s)
- Jan Coburger
- Department of Neurosurgery, University of Ulm, Günzburg, Germany
| | - Andreas Merkel
- Department of Neurosurgery, University of Erlangen, Erlangen, Germany
| | - Moritz Scherer
- Department of Neurosurgery, University of Heidelberg, Heidelberg, Germany
| | - Felix Schwartz
- Department of Neurosurgery, University of Schleswig-Holstein, Kiel, Germany
| | - Florian Gessler
- Department of Neurosurgery, University of Frankfurt, Frankfurt, Germany
| | - Constantin Roder
- Department of Neurosurgery, University of Tübingen, Tübingen, Germany
| | - Andrej Pala
- Department of Neurosurgery, University of Ulm, Günzburg, Germany
| | - Ralph König
- Department of Neurosurgery, University of Ulm, Günzburg, Germany
| | - Lars Bullinger
- Department of Internal Medicine III, University of Ulm, Ulm, Germany
| | - Gabriele Nagel
- Institute for Epidemiology and Medical Biometrics, University of Ulm, Ulm, Germany
| | - Christine Jungk
- Department of Neurosurgery, University of Heidelberg, Heidelberg, Germany
| | - Sotirios Bisdas
- Department of Neuroradiology, University of Tübingen, Tübingen, Germany
| | - Arya Nabavi
- Department of Neurosurgery, International Neuroscience Institute Hannover, Hannover, Germany
| | - Oliver Ganslandt
- Department of Neurosurgery, Klinikum Stuttgart, Stuttgart, Germany
| | - Volker Seifert
- Department of Neurosurgery, University of Frankfurt, Frankfurt, Germany
| | - Marcos Tatagiba
- Department of Neurosurgery, University of Tübingen, Tübingen, Germany
| | - Christian Senft
- Department of Neurosurgery, University of Frankfurt, Frankfurt, Germany
| | - Maximilian Mehdorn
- Department of Neurosurgery, University of Schleswig-Holstein, Kiel, Germany
| | | | - Karl Rössler
- Department of Neurosurgery, University of Erlangen, Erlangen, Germany
| | | |
Collapse
|
1371
|
Nakashima H, Kaufmann JK, Wang PY, Nguyen T, Speranza MC, Kasai K, Okemoto K, Otsuki A, Nakano I, Fernandez S, Goins WF, Grandi P, Glorioso JC, Lawler S, Cripe TP, Chiocca EA. Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma. J Clin Invest 2015; 125:4269-80. [PMID: 26524593 DOI: 10.1172/jci80713] [Citation(s) in RCA: 56] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2014] [Accepted: 09/10/2015] [Indexed: 12/15/2022] Open
Abstract
Oncolytic viral (OV) therapy, which uses genetically engineered tumor-targeting viruses, is being increasingly used in cancer clinical trials due to the direct cytolytic effects of this treatment that appear to provoke a robust immune response against the tumor. As OVs enter tumor cells, intrinsic host defenses have the potential to hinder viral replication and spread within the tumor mass. In this report, we show that histone deacetylase 6 (HDAC6) in tumor cells appears to alter the trafficking of post-entry OVs from the nucleus toward lysosomes. In glioma cell lines and glioma-stem-like cells, HDAC6 inhibition (HDAC6i) by either pharmacologic or genetic means substantially increased replication of oncolytic herpes simplex virus type 1 (oHSV). Moreover, HDAC6i increased shuttling of post-entry oHSV to the nucleus. In addition, electron microscopic analysis revealed that post-entry oHSVs are preferentially taken up into glioma cells through the endosomal pathway rather than via fusion at the cell surface. Together, these findings illustrate a mechanism of glioma cell defense against an incoming infection by oHSV and identify possible approaches to enhance oHSV replication and subsequent lysis of tumor cells.
Collapse
|
1372
|
Verreault M, Schmitt C, Goldwirt L, Pelton K, Haidar S, Levasseur C, Guehennec J, Knoff D, Labussière M, Marie Y, Ligon AH, Mokhtari K, Hoang-Xuan K, Sanson M, Alexander BM, Wen PY, Delattre JY, Ligon KL, Idbaih A. Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas. Clin Cancer Res 2015; 22:1185-96. [PMID: 26482041 DOI: 10.1158/1078-0432.ccr-15-1015] [Citation(s) in RCA: 83] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2015] [Accepted: 09/27/2015] [Indexed: 01/05/2023]
Abstract
PURPOSE p53 pathway alterations are key molecular events in glioblastoma (GBM). MDM2 inhibitors increase expression and stability of p53 and are presumed to be most efficacious in patients with TP53 wild-type and MDM2-amplified cancers. However, this biomarker hypothesis has not been tested in patients or patient-derived models for GBM. EXPERIMENTAL DESIGN We performed a preclinical evaluation of RG7112 MDM2 inhibitor, across a panel of 36 patient-derived GBM cell lines (PDCL), each genetically characterized according to their P53 pathway status. We then performed a pharmacokinetic (PK) profiling of RG7112 distribution in mice and evaluated the therapeutic activity of RG7112 in orthotopic and subcutaneous GBM models. RESULTS MDM2-amplified PDCLs were 44 times more sensitive than TP53-mutated lines that showed complete resistance at therapeutically attainable concentrations (avg. IC50 of 0.52 μmol/L vs. 21.9 μmol/L). MDM4-amplified PDCLs were highly sensitive but showed intermediate response (avg. IC50 of 1.2 μmol/L), whereas response was heterogeneous in TP53 wild-type PDCLs with normal MDM2/4 levels (avg. IC50 of 7.7 μmol/L). In MDM2-amplified lines, RG7112 restored p53 activity inducing robust p21 expression and apoptosis. PK profiling of RG7112-treated PDCL intracranial xenografts demonstrated that the compound significantly crosses the blood-brain and the blood-tumor barriers. Most importantly, treatment of MDM2-amplified/TP53 wild-type PDCL-derived model (subcutaneous and orthotopic) reduced tumor growth, was cytotoxic, and significantly increased survival. CONCLUSIONS These data strongly support development of MDM2 inhibitors for clinical testing in MDM2-amplified GBM patients. Moreover, significant efficacy in a subset of non-MDM2-amplified models suggests that additional markers of response to MDM2 inhibitors must be identified.
Collapse
Affiliation(s)
- Maite Verreault
- Inserm, U 1127, Paris, France. CNRS, UMR 7225, Paris, France. Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, Paris, France. Institut du Cerveau et de la Moëlle épinière, ICM, 47, Bd de l'Hôpital, Paris, France. Institut du Cerveau et de la Moëlle épinière, Centre de neuroimagerie de recherche, CHU Pitié-Salpêtrière, 47, Bd de l'Hôpital, Paris, France
| | - Charlotte Schmitt
- Inserm, U 1127, Paris, France. CNRS, UMR 7225, Paris, France. Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, Paris, France. Institut du Cerveau et de la Moëlle épinière, ICM, 47, Bd de l'Hôpital, Paris, France
| | - Lauriane Goldwirt
- Laboratoire de Pharmacologie Biologique, Hôpital Saint-Louis, 1, avenue Claude-Vellefaux, Paris, France
| | - Kristine Pelton
- Center for Neuro-oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts. Department of Pathology, Harvard Medical School, Boston, Massachusetts. Boston Children's Hospital, Boston, Massachusetts
| | - Samer Haidar
- Center for Neuro-oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts. Department of Pathology, Harvard Medical School, Boston, Massachusetts. Boston Children's Hospital, Boston, Massachusetts
| | - Camille Levasseur
- Inserm, U 1127, Paris, France. CNRS, UMR 7225, Paris, France. Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, Paris, France. Institut du Cerveau et de la Moëlle épinière, ICM, 47, Bd de l'Hôpital, Paris, France
| | - Jeremy Guehennec
- Inserm, U 1127, Paris, France. CNRS, UMR 7225, Paris, France. Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, Paris, France. Institut du Cerveau et de la Moëlle épinière, ICM, 47, Bd de l'Hôpital, Paris, France
| | - David Knoff
- Center for Neuro-oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts. Department of Pathology, Harvard Medical School, Boston, Massachusetts. Boston Children's Hospital, Boston, Massachusetts
| | - Marianne Labussière
- Inserm, U 1127, Paris, France. CNRS, UMR 7225, Paris, France. Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, Paris, France. Institut du Cerveau et de la Moëlle épinière, ICM, 47, Bd de l'Hôpital, Paris, France
| | - Yannick Marie
- Inserm, U 1127, Paris, France. CNRS, UMR 7225, Paris, France. Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, Paris, France. Institut du Cerveau et de la Moëlle épinière, ICM, 47, Bd de l'Hôpital, Paris, France
| | - Azra H Ligon
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts. Department of Pathology, Harvard Medical School, Boston, Massachusetts.
| | - Karima Mokhtari
- Inserm, U 1127, Paris, France. CNRS, UMR 7225, Paris, France. Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, Paris, France. Institut du Cerveau et de la Moëlle épinière, ICM, 47, Bd de l'Hôpital, Paris, France. AP-HP, Hôpital universitaire Pitié-Salpêtrière, Service de Neurologie 2-Mazarin, 47, Bd de l'Hôpital, Paris, France. AP-HP, Hôpital de la Pitié-Salpêtrière, Service de Neuropathologie R Escourolle, 47, Bd de l'Hôpital, Paris, France
| | - Khê Hoang-Xuan
- Inserm, U 1127, Paris, France. CNRS, UMR 7225, Paris, France. Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, Paris, France. Institut du Cerveau et de la Moëlle épinière, ICM, 47, Bd de l'Hôpital, Paris, France. AP-HP, Hôpital universitaire Pitié-Salpêtrière, Service de Neurologie 2-Mazarin, 47, Bd de l'Hôpital, Paris, France. AP-HP, Hôpital de la Pitié-Salpêtrière, Service de Neuropathologie R Escourolle, 47, Bd de l'Hôpital, Paris, France
| | - Marc Sanson
- Inserm, U 1127, Paris, France. CNRS, UMR 7225, Paris, France. Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, Paris, France. Institut du Cerveau et de la Moëlle épinière, ICM, 47, Bd de l'Hôpital, Paris, France. AP-HP, Hôpital universitaire Pitié-Salpêtrière, Service de Neurologie 2-Mazarin, 47, Bd de l'Hôpital, Paris, France. AP-HP, Hôpital de la Pitié-Salpêtrière, Service de Neuropathologie R Escourolle, 47, Bd de l'Hôpital, Paris, France. OncoNeuroThèque biobank, Institut du Cerveau et de la Moëlle épinière, ICM, 47, Bd de l'Hôpital, Paris, France
| | - Brian M Alexander
- Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts
| | - Patrick Y Wen
- Center for Neuro-oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Jean-Yves Delattre
- Inserm, U 1127, Paris, France. CNRS, UMR 7225, Paris, France. Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, Paris, France. Institut du Cerveau et de la Moëlle épinière, ICM, 47, Bd de l'Hôpital, Paris, France. AP-HP, Hôpital universitaire Pitié-Salpêtrière, Service de Neurologie 2-Mazarin, 47, Bd de l'Hôpital, Paris, France. AP-HP, Hôpital de la Pitié-Salpêtrière, Service de Neuropathologie R Escourolle, 47, Bd de l'Hôpital, Paris, France. OncoNeuroThèque biobank, Institut du Cerveau et de la Moëlle épinière, ICM, 47, Bd de l'Hôpital, Paris, France
| | - Keith L Ligon
- Center for Neuro-oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts. Department of Pathology, Harvard Medical School, Boston, Massachusetts. Boston Children's Hospital, Boston, Massachusetts
| | - Ahmed Idbaih
- Inserm, U 1127, Paris, France. CNRS, UMR 7225, Paris, France. Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, Paris, France. Institut du Cerveau et de la Moëlle épinière, ICM, 47, Bd de l'Hôpital, Paris, France. AP-HP, Hôpital universitaire Pitié-Salpêtrière, Service de Neurologie 2-Mazarin, 47, Bd de l'Hôpital, Paris, France. AP-HP, Hôpital de la Pitié-Salpêtrière, Service de Neuropathologie R Escourolle, 47, Bd de l'Hôpital, Paris, France.
| |
Collapse
|
1373
|
Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes. J Neurooncol 2015; 126:175-183. [PMID: 26459327 DOI: 10.1007/s11060-015-1957-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2015] [Accepted: 10/06/2015] [Indexed: 01/23/2023]
Abstract
Despite moderate improvements in outcome of glioblastoma after first-line treatment with chemoradiation recent clinical trials failed to improve the prognosis of recurrent glioblastoma. In the absence of a standard of care we aimed to investigate institutional treatment strategies to identify similarities and differences in the pattern of care for recurrent glioblastoma. We investigated re-treatment criteria and therapeutic pathways for recurrent glioblastoma of eight neuro-oncology centres in Switzerland having an established multidisciplinary tumour-board conference. Decision algorithms, differences and consensus were analysed using the objective consensus methodology. A total of 16 different treatment recommendations were identified based on combinations of eight different decision criteria. The set of criteria implemented as well as the set of treatments offered was different in each centre. For specific situations, up to 6 different treatment recommendations were provided by the eight centres. The only wide-range consensus identified was to offer best supportive care to unfit patients. A majority recommendation was identified for non-operable large early recurrence with unmethylated MGMT promoter status in the fit patients: here bevacizumab was offered. In fit patients with late recurrent non-operable MGMT promoter methylated glioblastoma temozolomide was recommended by most. No other majority recommendations were present. In the absence of strong evidence we identified few consensus recommendations in the treatment of recurrent glioblastoma. This contrasts the limited availability of single drugs and treatment modalities. Clinical situations of greatest heterogeneity may be suitable to be addressed in clinical trials and second opinion referrals are likely to yield diverging recommendations.
Collapse
|
1374
|
Kinnersley B, Labussière M, Holroyd A, Di Stefano AL, Broderick P, Vijayakrishnan J, Mokhtari K, Delattre JY, Gousias K, Schramm J, Schoemaker MJ, Fleming SJ, Herms S, Heilmann S, Schreiber S, Wichmann HE, Nöthen MM, Swerdlow A, Lathrop M, Simon M, Bondy M, Sanson M, Houlston RS. Genome-wide association study identifies multiple susceptibility loci for glioma. Nat Commun 2015; 6:8559. [PMID: 26424050 PMCID: PMC4600760 DOI: 10.1038/ncomms9559] [Citation(s) in RCA: 88] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2015] [Accepted: 09/04/2015] [Indexed: 12/25/2022] Open
Abstract
Previous genome-wide association studies (GWASs) have shown that common genetic variation contributes to the heritable risk of glioma. To identify new glioma susceptibility loci, we conducted a meta-analysis of four GWAS (totalling 4,147 cases and 7,435 controls), with imputation using 1000 Genomes and UK10K Project data as reference. After genotyping an additional 1,490 cases and 1,723 controls we identify new risk loci for glioblastoma (GBM) at 12q23.33 (rs3851634, near POLR3B, P=3.02 × 10(-9)) and non-GBM at 10q25.2 (rs11196067, near VTI1A, P=4.32 × 10(-8)), 11q23.2 (rs648044, near ZBTB16, P=6.26 × 10(-11)), 12q21.2 (rs12230172, P=7.53 × 10(-11)) and 15q24.2 (rs1801591, near ETFA, P=5.71 × 10(-9)). Our findings provide further insights into the genetic basis of the different glioma subtypes.
Collapse
Affiliation(s)
- Ben Kinnersley
- Division of Genetics and Epidemiology, The Institute of Cancer Research, London SM2 5NG, UK
| | - Marianne Labussière
- Sorbonne Universités UPMC Univ Paris 06, INSERM CNRS, U1127, UMR 7225, ICM, F-75013 Paris, France
| | - Amy Holroyd
- Division of Genetics and Epidemiology, The Institute of Cancer Research, London SM2 5NG, UK
| | - Anna-Luisa Di Stefano
- Sorbonne Universités UPMC Univ Paris 06, INSERM CNRS, U1127, UMR 7225, ICM, F-75013 Paris, France
- Onconeurotek, F-75013 Paris, France
- AP-HP, GH Pitié-Salpêtrière, Service de Neurologie 2, F-75013 Paris, France
| | - Peter Broderick
- Division of Genetics and Epidemiology, The Institute of Cancer Research, London SM2 5NG, UK
| | - Jayaram Vijayakrishnan
- Division of Genetics and Epidemiology, The Institute of Cancer Research, London SM2 5NG, UK
| | - Karima Mokhtari
- Sorbonne Universités UPMC Univ Paris 06, INSERM CNRS, U1127, UMR 7225, ICM, F-75013 Paris, France
- Onconeurotek, F-75013 Paris, France
- AP-HP, GH Pitié-Salpêtrière, Laboratoire de neuropathologie R Escourolle, F-75013 Paris, France
| | - Jean-Yves Delattre
- Sorbonne Universités UPMC Univ Paris 06, INSERM CNRS, U1127, UMR 7225, ICM, F-75013 Paris, France
- Onconeurotek, F-75013 Paris, France
- AP-HP, GH Pitié-Salpêtrière, Service de Neurologie 2, F-75013 Paris, France
| | - Konstantinos Gousias
- Department of Neurosurgery, University of Bonn Medical Center, Sigmund-Freud-Straße 25, 53105 Bonn, Germany
| | - Johannes Schramm
- Department of Neurosurgery, University of Bonn Medical Center, Sigmund-Freud-Straße 25, 53105 Bonn, Germany
| | - Minouk J. Schoemaker
- Division of Genetics and Epidemiology, The Institute of Cancer Research, London SM2 5NG, UK
| | - Sarah J. Fleming
- Centre for Epidemiology and Biostatistics, Faculty of Medicine and Health, University of Leeds, Leeds LS2 9JT, UK
| | - Stefan Herms
- Department of Biomedicine, Institute of Human Genetics, University of Bonn, 53127 Bonn, Germany
- Division of Medical Genetics, Department of Biomedicine, University of Basel, 4056 Basel, Switzerland
| | - Stefanie Heilmann
- Department of Biomedicine, Institute of Human Genetics, University of Bonn, 53127 Bonn, Germany
| | - Stefan Schreiber
- 1st Medical Department, University Clinic Schleswig-Holstein, Campus Kiel, House 6, Arnold-Heller-Straße 3, Kiel 24105, Germany
- Institute of Clinical Molecular Biology, Christian-Albrechts-University Kiel, Arnold-Heller-Straße 3, Kiel 24105, Germany
| | - Heinz-Erich Wichmann
- Institute of Epidemiology I, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany
- Institute of Medical Informatics, Biometry and Epidemiology, Chair of Epidemiology, Ludwig-Maximilians-Universität, 81377 Munich, Germany
| | - Markus M. Nöthen
- Department of Biomedicine, Institute of Human Genetics, University of Bonn, 53127 Bonn, Germany
| | - Anthony Swerdlow
- Division of Genetics and Epidemiology, The Institute of Cancer Research, London SM2 5NG, UK
- Division of Breast Cancer Research, The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
| | - Mark Lathrop
- AP-HP, GH Pitié-Salpêtrière, Laboratoire de neuropathologie R Escourolle, F-75013 Paris, France
- Foundation Jean Dausset-CEPH, 27 Rue Juliette Dodu, 75010 Paris, France
- Génome Québec, Department of Human Genetics, McGill University, Montreal, Quebec, Canada H3A 0G1
| | - Matthias Simon
- Department of Neurosurgery, University of Bonn Medical Center, Sigmund-Freud-Straße 25, 53105 Bonn, Germany
| | - Melissa Bondy
- Division of Hematology-Oncology, Department of Pediatrics, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA
| | - Marc Sanson
- Sorbonne Universités UPMC Univ Paris 06, INSERM CNRS, U1127, UMR 7225, ICM, F-75013 Paris, France
- Onconeurotek, F-75013 Paris, France
- AP-HP, GH Pitié-Salpêtrière, Service de Neurologie 2, F-75013 Paris, France
| | - Richard S. Houlston
- Division of Genetics and Epidemiology, The Institute of Cancer Research, London SM2 5NG, UK
| |
Collapse
|
1375
|
Bhattacharjee R, Devi A, Mishra S. Molecular docking and molecular dynamics studies reveal structural basis of inhibition and selectivity of inhibitors EGCG and OSU-03012 toward glucose regulated protein-78 (GRP78) overexpressed in glioblastoma. J Mol Model 2015; 21:272. [PMID: 26419972 DOI: 10.1007/s00894-015-2801-3] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2015] [Accepted: 08/26/2015] [Indexed: 01/02/2023]
Abstract
Glioblastoma (GBM), a malignant form of brain tumor, has a high mortality rate. GRP78, one of the HSP70 protein family members, is overexpressed in GBM. GRP78 is the key chaperone protein involved in the unfolded protein response. Upregulated GRP78 expression in cancer cells inhibits apoptosis and promotes chemoresistance. GRP78 has an ATPase domain, a substrate-binding domain, and a linker region. ATP-competitive inhibitors such as EGCG and OSU-03012 inhibit GRP78 activity and reduce its expression in GBM. However, there is a lack of structural data on the binding modes of these inhibitors to GRP78 ATPase domain. Further, the mode of selectivity of these inhibitors toward GRP78 also is unknown. Toward this end, molecular docking was performed with AutoDock Vina and confirmation obtained by docking using ROSIE. The stability and MM-PBSA binding energy of GRP78-inhibitor complexes as well as energetic contribution of individual residues was analyzed by 50 ns molecular dynamics run with GROMACS. MSA by ClustalW2 identified unique amino acid residues in the ATPase domain of GRP78 which were different from the residues present in other HSP70 proteins. Important and unique amino acid residues of GRP78 such as Ile61, Glu293, Arg297, and Arg367 played a major role in the intermolecular interactions with these inhibitors. The interactions with unique residues of GRP78 as compared with those of HSP70-1A provided the basis for selectivity. It was found that the binding affinity and specificity/selectivity of EGCG toward GRP78 was higher than that toward HSP70-1A, and selectivity was even better than OSU-03012. OSU-03012 was predicted to bind to GRP78. Analyses from MD runs showed tight binding and stability of complexes, and the highest number of hydrogen bonds during the trajectory runs were comparable to those found in the docking studies. Energetic contribution of individual inhibitor-interacting residues showed that energy values of Ile61 and Glu293 were among the most negative. These studies are, to the best of our knowledge, the first studies characterizing EGCG and OSU-03012 interactions with GRP78 on a structural basis and provide a significant insight into their binding modes, selectivity, and structural stability.
Collapse
Affiliation(s)
- Rituparna Bhattacharjee
- Department of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, 500046, India
| | - Arpita Devi
- Department of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, 500046, India
| | - Seema Mishra
- Department of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, 500046, India.
| |
Collapse
|
1376
|
Majchrzak-Celińska A, Słocińska M, Barciszewska AM, Nowak S, Baer-Dubowska W. Wnt pathway antagonists, SFRP1, SFRP2, SOX17, and PPP2R2B, are methylated in gliomas and SFRP1 methylation predicts shorter survival. J Appl Genet 2015; 57:189-97. [PMID: 26337424 PMCID: PMC4830852 DOI: 10.1007/s13353-015-0312-7] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2015] [Revised: 07/30/2015] [Accepted: 08/12/2015] [Indexed: 12/30/2022]
Abstract
The deregulation of Wnt signaling is observed in various cancers, including gliomas, and might be related to the methylation of the genes encoding antagonists of this signaling pathway. The aim of the study was to assess the methylation status of the promoter regions of six Wnt negative regulators and to determine their prognostic value in clinical samples of gliomas of different grades. The methylation of SFRP1, SFRP2, PPP2R2B, DKK1, SOX17, and DACH1 was analyzed in 64 glioma samples using methylation-specific polymerase chain reaction (MSP). The results were analyzed in correlation with clinicopathological data. Promoter methylation in at least one of the analyzed genes was found in 81.3 % of the tumors. All benign tumors [grade I according to the World Health Organization (WHO) classification] lacked the methylation of the studied genes, whereas grade II, III, and IV tumors were, in most cases, methylation-positive. The methylation index correlated with the patient's age. The most frequently methylated genes were SFRP1 and SFRP2 (73.4 % and 46.9 %, respectively), followed by SOX17 (20.3 %) and PPP2R2B (10.9 %); DKK1 and DACH1 were basically unmethylated (1.6 %). SFRP1 methylation negatively correlated with patients' survival time, and was significantly more frequent in older patients and those with higher grade tumors. Overall, the results of this study indicate that aberrant promoter methylation of Wnt pathway antagonists is common in gliomas, which may be the possible cause of up-regulation of this signaling pathway often observed in these tumors. Moreover, SFRP1 promoter methylation can be regarded as a potential indicator of glioma patients' survival.
Collapse
Affiliation(s)
| | - Marta Słocińska
- Department of Pharmaceutical Biochemistry, Poznan University of Medical Sciences, Poznań, Poland
| | - Anna-Maria Barciszewska
- Department and Clinic of Neurosurgery and Neurotraumatology, Poznan University of Medical Sciences, Poznań, Poland
| | - Stanisław Nowak
- Department and Clinic of Neurosurgery and Neurotraumatology, Poznan University of Medical Sciences, Poznań, Poland
| | - Wanda Baer-Dubowska
- Department of Pharmaceutical Biochemistry, Poznan University of Medical Sciences, Poznań, Poland.
| |
Collapse
|
1377
|
Rice T, Lachance DH, Molinaro AM, Eckel-Passow JE, Walsh KM, Barnholtz-Sloan J, Ostrom QT, Francis SS, Wiemels J, Jenkins RB, Wiencke JK, Wrensch MR. Understanding inherited genetic risk of adult glioma - a review. Neurooncol Pract 2015; 3:10-16. [PMID: 26941959 DOI: 10.1093/nop/npv026] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2015] [Indexed: 01/10/2023] Open
Abstract
During the past six years, researchers have made major progress identifying common inherited genetic variation that increases risk for primary adult glioma. This paper summarizes knowledge about rare familial cancer syndromes that include adult glioma and reviews the available literature on the more recently discovered common inherited variation. Ten independent inherited variants in eight chromosomal regions have been convincingly associated with increased risk for adult glioma. Most of these variants increase relative risk of primary adult glioma by 20% to 40%, but the TP53 variant rs78378222 confers a two-fold relative risk (ie, 200%), and rs557505857 on chromosome 8 confers a six-fold relative risk of IDH-mutated astrocytomas and oligodendroglial tumors (ie, 600%). Even with a six-fold relative risk, the overall risk of developing adult glioma is too low for screening for the high-risk variant on chromosome 8. Future studies will help clarify which inherited adult glioma risk variants are associated with subtypes defined by histology and/or acquired tumor mutations. This review also provides an information sheet for primary adult glioma patients and their families.
Collapse
Affiliation(s)
- Terri Rice
- Division of Neuroepidemiology, Department of Neurological Surgery , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (T.R., A.M.M., K.M.W, S.S.F., J.W., J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905 (D.H.L.) ; Department of Epidemiology and Biostatistics , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (A.M.M., J.W.); Division of Biomedical Statistics and Informatics , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (J.E.E.-P.); Program in Cancer Genetics, Helen Diller Family Comprehensive Cancer Center , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (K.M.W., J.W., J.K.W., M.R.W.); Case Comprehensive Cancer Center , Case Western Reserve University School of Medicine , 11100 Euclid Avenue, Cleveland, OH 44106-5065 (J.B.-S., Q.T.O.); Central Brain Tumor Registry of the United States , 244 East Ogden Ave Suite 116, Hinsdale, IL 60521 (J.B.-S., Q.T.O.)
| | - Daniel H Lachance
- Division of Neuroepidemiology, Department of Neurological Surgery , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (T.R., A.M.M., K.M.W, S.S.F., J.W., J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905 (D.H.L.) ; Department of Epidemiology and Biostatistics , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (A.M.M., J.W.); Division of Biomedical Statistics and Informatics , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (J.E.E.-P.); Program in Cancer Genetics, Helen Diller Family Comprehensive Cancer Center , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (K.M.W., J.W., J.K.W., M.R.W.); Case Comprehensive Cancer Center , Case Western Reserve University School of Medicine , 11100 Euclid Avenue, Cleveland, OH 44106-5065 (J.B.-S., Q.T.O.); Central Brain Tumor Registry of the United States , 244 East Ogden Ave Suite 116, Hinsdale, IL 60521 (J.B.-S., Q.T.O.)
| | - Annette M Molinaro
- Division of Neuroepidemiology, Department of Neurological Surgery , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (T.R., A.M.M., K.M.W, S.S.F., J.W., J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905 (D.H.L.) ; Department of Epidemiology and Biostatistics , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (A.M.M., J.W.); Division of Biomedical Statistics and Informatics , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (J.E.E.-P.); Program in Cancer Genetics, Helen Diller Family Comprehensive Cancer Center , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (K.M.W., J.W., J.K.W., M.R.W.); Case Comprehensive Cancer Center , Case Western Reserve University School of Medicine , 11100 Euclid Avenue, Cleveland, OH 44106-5065 (J.B.-S., Q.T.O.); Central Brain Tumor Registry of the United States , 244 East Ogden Ave Suite 116, Hinsdale, IL 60521 (J.B.-S., Q.T.O.)
| | - Jeanette E Eckel-Passow
- Division of Neuroepidemiology, Department of Neurological Surgery , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (T.R., A.M.M., K.M.W, S.S.F., J.W., J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905 (D.H.L.) ; Department of Epidemiology and Biostatistics , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (A.M.M., J.W.); Division of Biomedical Statistics and Informatics , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (J.E.E.-P.); Program in Cancer Genetics, Helen Diller Family Comprehensive Cancer Center , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (K.M.W., J.W., J.K.W., M.R.W.); Case Comprehensive Cancer Center , Case Western Reserve University School of Medicine , 11100 Euclid Avenue, Cleveland, OH 44106-5065 (J.B.-S., Q.T.O.); Central Brain Tumor Registry of the United States , 244 East Ogden Ave Suite 116, Hinsdale, IL 60521 (J.B.-S., Q.T.O.)
| | - Kyle M Walsh
- Division of Neuroepidemiology, Department of Neurological Surgery , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (T.R., A.M.M., K.M.W, S.S.F., J.W., J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905 (D.H.L.) ; Department of Epidemiology and Biostatistics , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (A.M.M., J.W.); Division of Biomedical Statistics and Informatics , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (J.E.E.-P.); Program in Cancer Genetics, Helen Diller Family Comprehensive Cancer Center , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (K.M.W., J.W., J.K.W., M.R.W.); Case Comprehensive Cancer Center , Case Western Reserve University School of Medicine , 11100 Euclid Avenue, Cleveland, OH 44106-5065 (J.B.-S., Q.T.O.); Central Brain Tumor Registry of the United States , 244 East Ogden Ave Suite 116, Hinsdale, IL 60521 (J.B.-S., Q.T.O.)
| | - Jill Barnholtz-Sloan
- Division of Neuroepidemiology, Department of Neurological Surgery , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (T.R., A.M.M., K.M.W, S.S.F., J.W., J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905 (D.H.L.) ; Department of Epidemiology and Biostatistics , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (A.M.M., J.W.); Division of Biomedical Statistics and Informatics , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (J.E.E.-P.); Program in Cancer Genetics, Helen Diller Family Comprehensive Cancer Center , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (K.M.W., J.W., J.K.W., M.R.W.); Case Comprehensive Cancer Center , Case Western Reserve University School of Medicine , 11100 Euclid Avenue, Cleveland, OH 44106-5065 (J.B.-S., Q.T.O.); Central Brain Tumor Registry of the United States , 244 East Ogden Ave Suite 116, Hinsdale, IL 60521 (J.B.-S., Q.T.O.)
| | - Quinn T Ostrom
- Division of Neuroepidemiology, Department of Neurological Surgery , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (T.R., A.M.M., K.M.W, S.S.F., J.W., J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905 (D.H.L.) ; Department of Epidemiology and Biostatistics , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (A.M.M., J.W.); Division of Biomedical Statistics and Informatics , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (J.E.E.-P.); Program in Cancer Genetics, Helen Diller Family Comprehensive Cancer Center , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (K.M.W., J.W., J.K.W., M.R.W.); Case Comprehensive Cancer Center , Case Western Reserve University School of Medicine , 11100 Euclid Avenue, Cleveland, OH 44106-5065 (J.B.-S., Q.T.O.); Central Brain Tumor Registry of the United States , 244 East Ogden Ave Suite 116, Hinsdale, IL 60521 (J.B.-S., Q.T.O.)
| | - Stephen S Francis
- Division of Neuroepidemiology, Department of Neurological Surgery , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (T.R., A.M.M., K.M.W, S.S.F., J.W., J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905 (D.H.L.) ; Department of Epidemiology and Biostatistics , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (A.M.M., J.W.); Division of Biomedical Statistics and Informatics , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (J.E.E.-P.); Program in Cancer Genetics, Helen Diller Family Comprehensive Cancer Center , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (K.M.W., J.W., J.K.W., M.R.W.); Case Comprehensive Cancer Center , Case Western Reserve University School of Medicine , 11100 Euclid Avenue, Cleveland, OH 44106-5065 (J.B.-S., Q.T.O.); Central Brain Tumor Registry of the United States , 244 East Ogden Ave Suite 116, Hinsdale, IL 60521 (J.B.-S., Q.T.O.)
| | - Joseph Wiemels
- Division of Neuroepidemiology, Department of Neurological Surgery , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (T.R., A.M.M., K.M.W, S.S.F., J.W., J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905 (D.H.L.) ; Department of Epidemiology and Biostatistics , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (A.M.M., J.W.); Division of Biomedical Statistics and Informatics , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (J.E.E.-P.); Program in Cancer Genetics, Helen Diller Family Comprehensive Cancer Center , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (K.M.W., J.W., J.K.W., M.R.W.); Case Comprehensive Cancer Center , Case Western Reserve University School of Medicine , 11100 Euclid Avenue, Cleveland, OH 44106-5065 (J.B.-S., Q.T.O.); Central Brain Tumor Registry of the United States , 244 East Ogden Ave Suite 116, Hinsdale, IL 60521 (J.B.-S., Q.T.O.)
| | - Robert B Jenkins
- Division of Neuroepidemiology, Department of Neurological Surgery , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (T.R., A.M.M., K.M.W, S.S.F., J.W., J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905 (D.H.L.) ; Department of Epidemiology and Biostatistics , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (A.M.M., J.W.); Division of Biomedical Statistics and Informatics , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (J.E.E.-P.); Program in Cancer Genetics, Helen Diller Family Comprehensive Cancer Center , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (K.M.W., J.W., J.K.W., M.R.W.); Case Comprehensive Cancer Center , Case Western Reserve University School of Medicine , 11100 Euclid Avenue, Cleveland, OH 44106-5065 (J.B.-S., Q.T.O.); Central Brain Tumor Registry of the United States , 244 East Ogden Ave Suite 116, Hinsdale, IL 60521 (J.B.-S., Q.T.O.)
| | - John K Wiencke
- Division of Neuroepidemiology, Department of Neurological Surgery , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (T.R., A.M.M., K.M.W, S.S.F., J.W., J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905 (D.H.L.) ; Department of Epidemiology and Biostatistics , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (A.M.M., J.W.); Division of Biomedical Statistics and Informatics , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (J.E.E.-P.); Program in Cancer Genetics, Helen Diller Family Comprehensive Cancer Center , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (K.M.W., J.W., J.K.W., M.R.W.); Case Comprehensive Cancer Center , Case Western Reserve University School of Medicine , 11100 Euclid Avenue, Cleveland, OH 44106-5065 (J.B.-S., Q.T.O.); Central Brain Tumor Registry of the United States , 244 East Ogden Ave Suite 116, Hinsdale, IL 60521 (J.B.-S., Q.T.O.)
| | - Margaret R Wrensch
- Division of Neuroepidemiology, Department of Neurological Surgery , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (T.R., A.M.M., K.M.W, S.S.F., J.W., J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905 (D.H.L.) ; Department of Epidemiology and Biostatistics , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (A.M.M., J.W.); Division of Biomedical Statistics and Informatics , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (J.E.E.-P.); Program in Cancer Genetics, Helen Diller Family Comprehensive Cancer Center , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (K.M.W., J.W., J.K.W., M.R.W.); Case Comprehensive Cancer Center , Case Western Reserve University School of Medicine , 11100 Euclid Avenue, Cleveland, OH 44106-5065 (J.B.-S., Q.T.O.); Central Brain Tumor Registry of the United States , 244 East Ogden Ave Suite 116, Hinsdale, IL 60521 (J.B.-S., Q.T.O.)
| |
Collapse
|
1378
|
Zhou M, Bracci PM, McCoy LS, Hsuang G, Wiemels JL, Rice T, Zheng S, Kelsey KT, Wrensch MR, Wiencke JK. Serum macrophage-derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival time. Int J Cancer 2015; 137:826-36. [PMID: 25604093 PMCID: PMC4478165 DOI: 10.1002/ijc.29441] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2014] [Accepted: 01/09/2015] [Indexed: 01/07/2023]
Abstract
Defects in antigen presenting cell function have been implicated in glioma immunosuppression. We measured peripheral CCL22, a dendritic cell/macrophage derived T cell trafficking chemokine, in sera from 1,208 glioma cases and 976 controls to assess whether it might provide a biomarker of glioma risk, survival and immune dysfunction. Cluster models were used to examine the relationship between CCL22 and glioma risk. Patient survival was assessed using Cox regression models. We also examined the relationship between CCL22 levels and CD4 cell counts, as well as allergy history and IgE levels. CCL22 levels were significantly lower among glioma cases compared with controls (Mean ± SEM: 1.23 ± 0.03 ng/mL in cases vs. 1.60 ± 0.03 ng/mL in controls, p < 0.0001) and this difference remained significant even after controlling for other covariates in the cluster models (highest quartile versus lowest Odds Ratio = 0.21, p < 0.0001). CD4 cell counts were positively correlated with CCL22 in glioma cases (Spearman r(2) = 0.51, p < 0.01) and were significantly lower in cases compared with controls. Higher CCL22 levels were associated with longer survival in all cases combined and in GBM cases (hazard ratio(allcases) = 0.81; 95% CI: 0.72-0.91, p = 0.0003). CCL22 levels were not associated with IgE level or self-reported allergies. Circulating CCL22 levels are related to both glioma risk and survival duration independent of age, histology, grade and IDH mutation status. CCL22 should be considered a marker of immune status with potential prognostic value.
Collapse
Affiliation(s)
- Mi Zhou
- Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA
| | - Paige M. Bracci
- Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA
| | - Lucie S. McCoy
- Department of Neurological Surgery, School of Medicine, University of California San Francisco, San Francisco, CA
| | - George Hsuang
- Department of Neurological Surgery, School of Medicine, University of California San Francisco, San Francisco, CA
| | - Joseph L. Wiemels
- Department of Neurological Surgery, School of Medicine, University of California San Francisco, San Francisco, CA
- Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA
| | - Terri Rice
- Department of Neurological Surgery, School of Medicine, University of California San Francisco, San Francisco, CA
| | - Shichun Zheng
- Department of Neurological Surgery, School of Medicine, University of California San Francisco, San Francisco, CA
| | - Karl T. Kelsey
- Department of Laboratory Medicine and Pathology, Brown University, Providence, RI
| | - Margaret R. Wrensch
- Department of Neurological Surgery, School of Medicine, University of California San Francisco, San Francisco, CA
- Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA
| | - John K. Wiencke
- Department of Neurological Surgery, School of Medicine, University of California San Francisco, San Francisco, CA
- Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA
| |
Collapse
|
1379
|
Johnson DR, Fogh SE, Giannini C, Kaufmann TJ, Raghunathan A, Theodosopoulos PV, Clarke JL. Case-Based Review: newly diagnosed glioblastoma. Neurooncol Pract 2015; 2:106-121. [PMID: 31386093 DOI: 10.1093/nop/npv020] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2015] [Indexed: 12/28/2022] Open
Abstract
Glioblastoma (WHO grade IV astrocytoma) is the most common and most aggressive primary brain tumor in adults. Optimal treatment of a patient with glioblastoma requires collaborative care across numerous specialties. The diagnosis of glioblastoma may be suggested by the symptomatic presentation and imaging, but it must be pathologically confirmed via surgery, which can have dual diagnostic and therapeutic roles. Standard of care postsurgical treatment for newly diagnosed patients involves radiation therapy and oral temozolomide chemotherapy. Despite numerous recent trials of novel therapeutic approaches, this standard of care has not changed in over a decade. Treatment options under active investigation include molecularly targeted therapies, immunotherapeutic approaches, and the use of alternating electrical field to disrupt tumor cell division. These trials may be aided by new insights into glioblastoma heterogeneity, allowing for focused evaluation of new treatments in the patient subpopulations most likely to benefit from them. Because glioblastoma is incurable by current therapies, frequent clinical and radiographic assessment is needed after initial treatment to allow for early intervention upon progressive tumor when it occurs.
Collapse
Affiliation(s)
- Derek R Johnson
- Department of Neurology and Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota (D.R.J.); Department of Radiation Oncology, University of California, San Francisco, California (S.E.F.); Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (C.G., A.R.); Department of Radiology, Mayo Clinic, Rochester, Minnesota (T.J.K.); Department of Neurological Surgery, University of California, San Francisco, California (P.V.T.); Department of Neurology and Department of Neurological Surgery, University of California, San Francisco, California (J.L.C.)
| | - Shannon E Fogh
- Department of Neurology and Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota (D.R.J.); Department of Radiation Oncology, University of California, San Francisco, California (S.E.F.); Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (C.G., A.R.); Department of Radiology, Mayo Clinic, Rochester, Minnesota (T.J.K.); Department of Neurological Surgery, University of California, San Francisco, California (P.V.T.); Department of Neurology and Department of Neurological Surgery, University of California, San Francisco, California (J.L.C.)
| | - Caterina Giannini
- Department of Neurology and Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota (D.R.J.); Department of Radiation Oncology, University of California, San Francisco, California (S.E.F.); Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (C.G., A.R.); Department of Radiology, Mayo Clinic, Rochester, Minnesota (T.J.K.); Department of Neurological Surgery, University of California, San Francisco, California (P.V.T.); Department of Neurology and Department of Neurological Surgery, University of California, San Francisco, California (J.L.C.)
| | - Timothy J Kaufmann
- Department of Neurology and Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota (D.R.J.); Department of Radiation Oncology, University of California, San Francisco, California (S.E.F.); Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (C.G., A.R.); Department of Radiology, Mayo Clinic, Rochester, Minnesota (T.J.K.); Department of Neurological Surgery, University of California, San Francisco, California (P.V.T.); Department of Neurology and Department of Neurological Surgery, University of California, San Francisco, California (J.L.C.)
| | - Aditya Raghunathan
- Department of Neurology and Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota (D.R.J.); Department of Radiation Oncology, University of California, San Francisco, California (S.E.F.); Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (C.G., A.R.); Department of Radiology, Mayo Clinic, Rochester, Minnesota (T.J.K.); Department of Neurological Surgery, University of California, San Francisco, California (P.V.T.); Department of Neurology and Department of Neurological Surgery, University of California, San Francisco, California (J.L.C.)
| | - Philip V Theodosopoulos
- Department of Neurology and Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota (D.R.J.); Department of Radiation Oncology, University of California, San Francisco, California (S.E.F.); Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (C.G., A.R.); Department of Radiology, Mayo Clinic, Rochester, Minnesota (T.J.K.); Department of Neurological Surgery, University of California, San Francisco, California (P.V.T.); Department of Neurology and Department of Neurological Surgery, University of California, San Francisco, California (J.L.C.)
| | - Jennifer L Clarke
- Department of Neurology and Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota (D.R.J.); Department of Radiation Oncology, University of California, San Francisco, California (S.E.F.); Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (C.G., A.R.); Department of Radiology, Mayo Clinic, Rochester, Minnesota (T.J.K.); Department of Neurological Surgery, University of California, San Francisco, California (P.V.T.); Department of Neurology and Department of Neurological Surgery, University of California, San Francisco, California (J.L.C.)
| |
Collapse
|
1380
|
Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, Nishikawa R, Rosenthal M, Wen PY, Stupp R, Reifenberger G. Glioma. Nat Rev Dis Primers 2015; 1:15017. [PMID: 27188790 DOI: 10.1038/nrdp.2015.17] [Citation(s) in RCA: 651] [Impact Index Per Article: 72.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Gliomas are primary brain tumours that are thought to derive from neuroglial stem or progenitor cells. On the basis of their histological appearance, they have been traditionally classified as astrocytic, oligodendroglial or ependymal tumours and assigned WHO grades I-IV, which indicate different degrees of malignancy. Tremendous progress in genomic, transcriptomic and epigenetic profiling has resulted in new concepts of classifying and treating gliomas. Diffusely infiltrating gliomas in adults are now separated into three overarching tumour groups with distinct natural histories, responses to treatment and outcomes: isocitrate dehydrogenase (IDH)-mutant, 1p/19q co-deleted tumours with mostly oligodendroglial morphology that are associated with the best prognosis; IDH-mutant, 1p/19q non-co-deleted tumours with mostly astrocytic histology that are associated with intermediate outcome; and IDH wild-type, mostly higher WHO grade (III or IV) tumours that are associated with poor prognosis. Gliomas in children are molecularly distinct from those in adults, the majority being WHO grade I pilocytic astrocytomas characterized by circumscribed growth, favourable prognosis and frequent BRAF gene fusions or mutations. Ependymal tumours can be molecularly subdivided into distinct epigenetic subgroups according to location and prognosis. Although surgery, radiotherapy and alkylating agent chemotherapy are still the mainstay of treatment, individually tailored strategies based on tumour-intrinsic dominant signalling pathways and antigenic tumour profiles may ultimately improve outcome. For an illustrated summary of this Primer, visit: http://go.nature.com/TXY7Ri.
Collapse
Affiliation(s)
- Michael Weller
- Department of Neurology and Brain Tumor Center, University Hospital Zurich and University of Zurich, Frauenklinikstrasse 26, CH-8091 Zurich, Switzerland
| | - Wolfgang Wick
- Neurology Clinic, University of Heidelberg and German Cancer Research Center, Heidelberg, Germany
| | - Ken Aldape
- Department of Pathology, University Health Network, Toronto, Ontario, Canada
| | - Michael Brada
- Department of Molecular and Clinical Cancer Medicine and Department of Radiation Oncology, University of Liverpool and Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK
| | - Mitchell Berger
- Department of Neurological Surgery and Brain Tumor Research Center, University of California, San Francisco, California, USA
| | - Stefan M Pfister
- Division of Pediatric Neuro-Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of Pediatric Haematology and Oncology, Heidelberg University Hospital, Heidelberg, Germany
| | - Ryo Nishikawa
- Department of Neuro-Oncology and Neurosurgery, Saitama Medical University, Saitama, Japan
| | - Mark Rosenthal
- Department of Medical Oncology, The Royal Melbourne Hospital, Victoria 3050, Australia
| | - Patrick Y Wen
- Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA
| | - Roger Stupp
- Department of Oncology and Brain Tumor Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland
| | - Guido Reifenberger
- Department of Neuropathology, Heinrich Heine University Düsseldorf, and German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) Heidelberg, partner site Essen/Düsseldorf, Germany
| |
Collapse
|
1381
|
Jiang C, Shen F, Du J, Wang X, Su J, Liu Z, Huang X. DNA repair gene ERCC1 polymorphisms and glioma susceptibility among Chinese population: a meta-analysis. Int J Clin Exp Med 2015; 8:10248-10255. [PMID: 26379816 PMCID: PMC4565199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2015] [Accepted: 06/10/2015] [Indexed: 06/05/2023]
Abstract
BACKGROUND Excision repair cross complementation group 1 (ERCC1) has been shown to be involved in the progression of glioma susceptibility. However, the results remain conflict. The aim of this study was to systematically review and evaluate the role of ERCC1 C118T and C8092A polymorphisms in glioma risk among Chinese population. METHODS Related case-control studies were searched in online electronic databases. Odds ratio (OR) with its 95% confidence interval (CI) were employed to calculate the extracted data. RESULTS Total seven articles were retrieved, including 4426 subjects (1926 were glioma patients and 2500 were matched controls). No significant heterogeneity was found between studies (I(2)=0%, P>0.01). Our results demonstrated that A allele and AA genotype of ERCC1 C8092A polymorphism have a positive association with increasing the risk of glioma in the fixed-effect model (A vs. C: OR=1.13, 95% CI=1.02-1.25, P=0.02; AA vs. CC: OR=1.29, 95% CI=1.04-1.61, P=0.02; AA vs. CA+CC: OR=1.25, 95% CI=1.01-1.55, P=0.04). However, no significant relationship was found between C118T variant and glioma susceptibility. CONCLUSIONS Our results indicated that ERCC1 C8092A, not C118T polymorphism might be a biomarker for patients with glioma among Chinese population. Future studies with more ethnicities are needed to explore the precise association.
Collapse
Affiliation(s)
- Chunming Jiang
- Department of Pediatrics, Affiliated Hangzhou Hospital of Nanjing Medical University, Hangzhou First People’s HospitalHangzhou 301103, Zhejiang, P. R. China
| | - Fang Shen
- Department of psychiatry, Tongde Hospital of Zhejiang ProvinceHangzhou 301103, Zhejiang, P. R. China
| | - Jianmin Du
- Department of Pediatrics, Affiliated Hangzhou Hospital of Nanjing Medical University, Hangzhou First People’s HospitalHangzhou 301103, Zhejiang, P. R. China
| | - Xiaohua Wang
- Nanjing First Hospital, Nanjing Medical UniversityNanjing 210029, Jiangsu, P. R. China
| | - Jin Su
- Department of Pediatrics, The First Affiliated Hospital of Nanjing Medical UniversityNanjing 210029, Jiangsu, P. R. China
| | - Zhanli Liu
- Department of Pediatrics, Affiliated Hangzhou Hospital of Nanjing Medical University, Hangzhou First People’s HospitalHangzhou 301103, Zhejiang, P. R. China
| | - Xianmei Huang
- Department of Pediatrics, Affiliated Hangzhou Hospital of Nanjing Medical University, Hangzhou First People’s HospitalHangzhou 301103, Zhejiang, P. R. China
| |
Collapse
|
1382
|
Aum DJ, Kim DH, Beaumont TL, Leuthardt EC, Dunn GP, Kim AH. Molecular and cellular heterogeneity: the hallmark of glioblastoma. Neurosurg Focus 2015; 37:E11. [PMID: 25434380 DOI: 10.3171/2014.9.focus14521] [Citation(s) in RCA: 128] [Impact Index Per Article: 14.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
There has been increasing awareness that glioblastoma, which may seem histopathologically similar across many tumors, actually represents a group of molecularly distinct tumors. Emerging evidence suggests that cells even within the same tumor exhibit wide-ranging molecular diversity. Parallel to the discoveries of molecular heterogeneity among tumors and their individual cells, intense investigation of the cellular biology of glioblastoma has revealed that not all cancer cells within a given tumor behave the same. The identification of a subpopulation of brain tumor cells termed "glioblastoma cancer stem cells" or "tumor-initiating cells" has implications for the management of glioblastoma. This focused review will therefore summarize emerging concepts on the molecular and cellular heterogeneity of glioblastoma and emphasize that we should begin to consider each individual glioblastoma to be an ensemble of molecularly distinct subclones that reflect a spectrum of dynamic cell states.
Collapse
|
1383
|
FENG YA, LIU TE, WU YUNCHENG. microRNA-182 inhibits the proliferation and migration of glioma cells through the induction of neuritin expression. Oncol Lett 2015; 10:1197-1203. [DOI: 10.3892/ol.2015.3365] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2014] [Accepted: 05/20/2015] [Indexed: 11/05/2022] Open
|
1384
|
Zhao M, Xu H, Zhang B, Hong B, Yan W, Zhang J. Impact of nuclear factor erythroid-derived 2–like 2 and p62/sequestosome expression on prognosis of patients with gliomas. Hum Pathol 2015; 46:843-9. [DOI: 10.1016/j.humpath.2015.02.009] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/04/2014] [Revised: 02/13/2015] [Accepted: 02/19/2015] [Indexed: 12/27/2022]
|
1385
|
Idbaih A, Duran-Peña A, Bonnet C, Ducray F. Input of molecular analysis in medical management of primary brain tumor patients. Rev Neurol (Paris) 2015; 171:457-65. [PMID: 26026669 DOI: 10.1016/j.neurol.2015.04.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2015] [Revised: 03/22/2015] [Accepted: 04/10/2015] [Indexed: 01/04/2023]
Abstract
Primary brain tumors comprise a large group of malignant and non-malignant tumors including heterogeneous entities with various biological and clinical behaviors. Up till recently, diagnosis of brain cancers, that drives treatment decision-making, was based on integration of clinical, radiological and pathological features of patients and tumors. Over the last years, practical neuro-oncology has entered an era of molecular-based personalized medicine. Indeed, molecular features of tumors provide critical information to physicians for daily clinical management of patients and for design of relevant clinical research. Sporadic gliomas or glial tumors are the most common primary brain tumors in adults. Recently, their medical management has been revolutionized by molecular data. Indeed, optimal therapeutic management of grade III glioma patients now requires assessment of chromosome arms 1p/19q copy number and IDH mutational statuses as predictive and prognostic biomarkers. Indeed, two large phase III clinical trials have demonstrated that early chemotherapy plus radiotherapy, versus radiotherapy alone, doubles median overall survival of patients suffering from 1p/19q co-deleted and/or IDH mutated anaplastic oligodendroglial tumor. Interestingly, both biomarkers have been identified in a large proportion of WHO grade II gliomas. Their clinical value, in this population, is under investigation through multiple phase III clinical trials. In sporadic WHO grade I gliomas, and specifically in pilocytic astrocytomas, MAPK signaling pathway activation is a frequent event, mainly due to genetic alterations involving BRAF gene. This characteristic opens new therapeutic perspectives using MAPK signaling pathway inhibitors. Finally, in the most aggressive gliomas, WHO grade IV gliomas, two critical biomarkers have been identified: (i) MGMT promoter methylation associated with longer survival and better response to chemotherapy and (ii) IDH mutations predicting better prognosis. Although, further studies are needed, MGMT promoter methylation will undoubtedly be transferred soon to clinical practice. Molecular characteristics are beginning to be valuable and indispensable in neuro-oncology for better management of brain tumors patients. The near future will be marked by identification of novel molecular biomarkers and their validation for clinical practice.
Collapse
Affiliation(s)
- A Idbaih
- AP-HP, Hopital Universitaire La Pitié-Salpêtrière, Service de neurologie 2-Mazarin, 47-83, boulevard de l'Hôpital, 75013 Paris, France; Sorbonne Universités, UPMC Université Paris 06, UM 75, ICM, 47, boulevard de l'Hôpital, 75013 Paris, France; Inserm, U 1127, ICM, 47, boulevard de l'Hôpital, 75013 Paris, France; CNRS, UMR 7225, ICM, 47, boulevard de l'Hôpital, 75013 Paris, France; ICM, 47, boulevard de l'Hôpital, 75013 Paris, France.
| | - A Duran-Peña
- AP-HP, Hopital Universitaire La Pitié-Salpêtrière, Service de neurologie 2-Mazarin, 47-83, boulevard de l'Hôpital, 75013 Paris, France; Sorbonne Universités, UPMC Université Paris 06, UM 75, ICM, 47, boulevard de l'Hôpital, 75013 Paris, France; Inserm, U 1127, ICM, 47, boulevard de l'Hôpital, 75013 Paris, France; CNRS, UMR 7225, ICM, 47, boulevard de l'Hôpital, 75013 Paris, France; ICM, 47, boulevard de l'Hôpital, 75013 Paris, France
| | - C Bonnet
- Service de Neuro-oncologie, Hôpital Neurologique, Hospices Civils de Lyon, 3, quai des Célestins, 69002 Lyon, France; Université Claude-Bernard Lyon 1, 43, boulevard du 11 Novembre 1918, 69100 Villeurbanne, France
| | - F Ducray
- Service de Neuro-oncologie, Hôpital Neurologique, Hospices Civils de Lyon, 3, quai des Célestins, 69002 Lyon, France; Université Claude-Bernard Lyon 1, 43, boulevard du 11 Novembre 1918, 69100 Villeurbanne, France
| |
Collapse
|
1386
|
Walsh KM, Wiencke JK, Lachance DH, Wiemels JL, Molinaro AM, Eckel-Passow JE, Jenkins RB, Wrensch MR. Telomere maintenance and the etiology of adult glioma. Neuro Oncol 2015; 17:1445-52. [PMID: 26014050 DOI: 10.1093/neuonc/nov082] [Citation(s) in RCA: 57] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2014] [Accepted: 04/08/2015] [Indexed: 12/16/2022] Open
Abstract
A growing body of epidemiologic and tumor genomic research has identified an important role for telomere maintenance in glioma susceptibility, initiation, and prognosis. Telomere length has long been investigated in relation to cancer, but whether longer or shorter telomere length might be associated with glioma risk has remained elusive. Recent data address this question and are reviewed here. Common inherited variants near the telomerase-component genes TERC and TERT are associated both with longer telomere length and increased risk of glioma. Exome sequencing of glioma patients from families with multiple affected members has identified rare inherited mutations in POT1 (protection of telomeres protein 1) as high-penetrance glioma risk factors. These heritable POT1 mutations are also associated with increased telomere length in leukocytes. Tumor sequencing studies further indicate that acquired somatic mutations of TERT and ATRX are among the most frequent alterations found in adult gliomas. These mutations facilitate telomere lengthening, thus bypassing a critical mechanism of apoptosis. Although future research is needed, mounting evidence suggests that glioma is, at least in part, a disease of telomere dysregulation. Specifically, several inherited and acquired variants underlying gliomagenesis affect telomere pathways and are also associated with increased telomere length.
Collapse
Affiliation(s)
- Kyle M Walsh
- Department of Neurological Surgery, University of California-San Francisco, San Francisco, California (K.M.W., J.K.W., A.M.M., M.R.W.); Institute for Human Genetics, University of California-San Francisco, San Francisco, California (J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic, Rochester, Minnesota (D.H.L.); Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, California (J.L.W., A.M.M.); Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota (J.E.E.-P.)
| | - John K Wiencke
- Department of Neurological Surgery, University of California-San Francisco, San Francisco, California (K.M.W., J.K.W., A.M.M., M.R.W.); Institute for Human Genetics, University of California-San Francisco, San Francisco, California (J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic, Rochester, Minnesota (D.H.L.); Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, California (J.L.W., A.M.M.); Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota (J.E.E.-P.)
| | - Daniel H Lachance
- Department of Neurological Surgery, University of California-San Francisco, San Francisco, California (K.M.W., J.K.W., A.M.M., M.R.W.); Institute for Human Genetics, University of California-San Francisco, San Francisco, California (J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic, Rochester, Minnesota (D.H.L.); Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, California (J.L.W., A.M.M.); Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota (J.E.E.-P.)
| | - Joseph L Wiemels
- Department of Neurological Surgery, University of California-San Francisco, San Francisco, California (K.M.W., J.K.W., A.M.M., M.R.W.); Institute for Human Genetics, University of California-San Francisco, San Francisco, California (J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic, Rochester, Minnesota (D.H.L.); Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, California (J.L.W., A.M.M.); Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota (J.E.E.-P.)
| | - Annette M Molinaro
- Department of Neurological Surgery, University of California-San Francisco, San Francisco, California (K.M.W., J.K.W., A.M.M., M.R.W.); Institute for Human Genetics, University of California-San Francisco, San Francisco, California (J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic, Rochester, Minnesota (D.H.L.); Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, California (J.L.W., A.M.M.); Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota (J.E.E.-P.)
| | - Jeanette E Eckel-Passow
- Department of Neurological Surgery, University of California-San Francisco, San Francisco, California (K.M.W., J.K.W., A.M.M., M.R.W.); Institute for Human Genetics, University of California-San Francisco, San Francisco, California (J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic, Rochester, Minnesota (D.H.L.); Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, California (J.L.W., A.M.M.); Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota (J.E.E.-P.)
| | - Robert B Jenkins
- Department of Neurological Surgery, University of California-San Francisco, San Francisco, California (K.M.W., J.K.W., A.M.M., M.R.W.); Institute for Human Genetics, University of California-San Francisco, San Francisco, California (J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic, Rochester, Minnesota (D.H.L.); Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, California (J.L.W., A.M.M.); Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota (J.E.E.-P.)
| | - Margaret R Wrensch
- Department of Neurological Surgery, University of California-San Francisco, San Francisco, California (K.M.W., J.K.W., A.M.M., M.R.W.); Institute for Human Genetics, University of California-San Francisco, San Francisco, California (J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic, Rochester, Minnesota (D.H.L.); Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, California (J.L.W., A.M.M.); Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota (J.E.E.-P.)
| |
Collapse
|
1387
|
Leroy HA, Vermandel M, Lejeune JP, Mordon S, Reyns N. Fluorescence guided resection and glioblastoma in 2015: A review. Lasers Surg Med 2015; 47:441-51. [DOI: 10.1002/lsm.22359] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/23/2015] [Indexed: 12/31/2022]
Affiliation(s)
- Henri-Arthur Leroy
- INSERM; U1189 ONCO-THAI; Lille France
- CHRU de lille; Department of Neurosurgery; Lille France
- University of Lille; Lille France
| | - Maximilien Vermandel
- INSERM; U1189 ONCO-THAI; Lille France
- CHRU de lille; Department of Neurosurgery; Lille France
- University of Lille; Lille France
| | - Jean-Paul Lejeune
- INSERM; U1189 ONCO-THAI; Lille France
- CHRU de lille; Department of Neurosurgery; Lille France
- University of Lille; Lille France
| | | | - Nicolas Reyns
- INSERM; U1189 ONCO-THAI; Lille France
- CHRU de lille; Department of Neurosurgery; Lille France
- University of Lille; Lille France
| |
Collapse
|
1388
|
Heidenreich B, Rachakonda PS, Hosen I, Volz F, Hemminki K, Weyerbrock A, Kumar R. TERT promoter mutations and telomere length in adult malignant gliomas and recurrences. Oncotarget 2015; 6:10617-33. [PMID: 25797251 PMCID: PMC4496380 DOI: 10.18632/oncotarget.3329] [Citation(s) in RCA: 65] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2015] [Accepted: 02/09/2015] [Indexed: 02/03/2023] Open
Abstract
In this report on 303 gliomas we show the highest frequency of TERT promoter mutations in gliobastomas (80%) followed by oligodendrogliomas (70%) and astrocytomas (39%). We observed positive association between TERT promoter and IDH mutations in oligodendroglial tumors (OR = 26.3; 95% CI 2.5-250.2) and inverse association in primary glioblastomas (OR = 0.13; 95% CI 0.03-0.58). Tumors with TERT promoter mutations compared to those without showed increased TERT transcription; we also showed difference in the transcription levels due to the two main mutations. Tumors with TERT promoter mutations had shorter telomeres than those without. The patients with only TERT promoter mutations showed worst survival (median survival 14.6 months) and patients with both IDH and TERT promoter mutations showed best survival (246.5 months). In patients with astrocytoma, the TERT promoter mutations only associated with poor survival (P < 0.0001); IDH mutations and 1p/19q deletions associated with increased survival (P = 0.0004). TERT promoter mutations in low grade gliomas associated with reduced progression free survival (HR 10.2; 95% CI 1.9 - 55.9). While our data affirm the role of TERT promoter mutations in glial tumors, effects on transcription and telomere length emphasise the importance of telomere biology in disease genesis and outcome.
Collapse
Affiliation(s)
- Barbara Heidenreich
- Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg 69120, Germany
| | | | - Ismail Hosen
- Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg 69120, Germany
| | - Florian Volz
- Department of Neurosurgery, University Medical Center Freiburg, Freiburg 79106, Germany
| | - Kari Hemminki
- Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg 69120, Germany
- Center for Primary Health Care Research, Lund University, Malmö, Lund 22100, Sweden
| | - Astrid Weyerbrock
- Department of Neurosurgery, University Medical Center Freiburg, Freiburg 79106, Germany
| | - Rajiv Kumar
- Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg 69120, Germany
| |
Collapse
|
1389
|
Kiviniemi A, Gardberg M, Frantzén J, Pesola M, Vuorinen V, Parkkola R, Tolvanen T, Suilamo S, Johansson J, Luoto P, Kemppainen J, Roivainen A, Minn H. Somatostatin receptor subtype 2 in high-grade gliomas: PET/CT with (68)Ga-DOTA-peptides, correlation to prognostic markers, and implications for targeted radiotherapy. EJNMMI Res 2015; 5:25. [PMID: 25977882 PMCID: PMC4420768 DOI: 10.1186/s13550-015-0106-2] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2015] [Accepted: 04/14/2015] [Indexed: 01/20/2023] Open
Abstract
Background High-grade gliomas (HGGs) express somatostatin receptors (SSTR), rendering them candidates for peptide receptor radionuclide therapy (PRRT). Our purpose was to evaluate the potential of 68Ga-DOTA-1-Nal3-octreotide (68Ga-DOTANOC) or 68Ga-DOTA-Tyr3-octreotide (68Ga-DOTATOC) to target SSTR subtype 2 (SSTR2) in HGGs, and to study the association between SSTR2 expression and established biomarkers. Methods Twenty-seven patients (mean age 52 years) with primary or recurrent HGG prospectively underwent 68Ga-DOTA-peptide positron emission tomography/computed tomography (PET/CT) before resection. Maximum standardized uptake values (SUVmax) and receptor binding potential (BP) were calculated on PET/CT and disruption of blood–brain barrier (BBB) from contrast-enhanced T1-weighted magnetic resonance imaging (MRI-T1-Gad). Tumor volume concordance between PET and MRI-T1-Gad was assessed by Dice similarity coefficient (DC) and correlation by Spearman’s rank. Immunohistochemically determined SSTR2 status was compared to receptor imaging findings, prognostic biomarkers, and survival with Kruskal-Wallis, Pearson chi-square, and multivariate Cox regression, respectively. Results All 19 HGGs with disrupted BBB demonstrated tracer uptake. Tumor SUVmax (2.25 ± 1.33) correlated with MRI-T1-Gad (r = 0.713, P = 0.001) although DC 0.41 ± 0.19 suggested limited concordance. SSTR2 immunohistochemistry was regarded as positive in nine HGGs (32%) but no correlation with SUVmax or BP was found. By contrast, SSTR2 expression was associated with IDH1 mutation (P = 0.007), oligodendroglioma component (P = 0.010), lower grade (P = 0.005), absence of EGFR amplification (P = 0.021), and longer progression-free survival (HR 0.161, CI 0.037 to 0.704, P = 0.015). Conclusions In HGGs, uptake of 68Ga-DOTA-peptides is associated with disrupted BBB and cannot be predicted by SSTR2 immunohistochemistry. Thus, PET/CT shows limited value to detect HGGs suitable for PRRT. However, high SSTR2 expression portends favorable outcome along with established biomarkers such as IDH1 mutation. Trial registration ClinicalTrials.gov NCT01460706
Collapse
Affiliation(s)
- Aida Kiviniemi
- Turku PET Centre, Turku University Hospital, University of Turku, Kiinamyllynkatu 4-8, 20521 Turku, Finland ; Department of Radiology, Medical Imaging Centre of Southwest Finland, Turku University Hospital, Kiinamyllynkatu 4-8, 20521 Turku, Finland
| | - Maria Gardberg
- Department of Pathology, Turku University Hospital, Kiinamyllynkatu 4-8, 20521 Turku, Finland
| | - Janek Frantzén
- Department of Neurosurgery, Turku University Hospital, Hämeentie 11, 20521 Turku, Finland
| | - Marko Pesola
- Turku PET Centre, Turku University Hospital, University of Turku, Kiinamyllynkatu 4-8, 20521 Turku, Finland
| | - Ville Vuorinen
- Department of Neurosurgery, Turku University Hospital, Hämeentie 11, 20521 Turku, Finland
| | - Riitta Parkkola
- Department of Radiology, Medical Imaging Centre of Southwest Finland, Turku University Hospital, Kiinamyllynkatu 4-8, 20521 Turku, Finland
| | - Tuula Tolvanen
- Turku PET Centre, Turku University Hospital, University of Turku, Kiinamyllynkatu 4-8, 20521 Turku, Finland
| | - Sami Suilamo
- Department of Oncology and Radiotherapy, Turku University Hospital, Hämeentie 11, 20521 Turku, Finland
| | - Jarkko Johansson
- Turku PET Centre, Turku University Hospital, University of Turku, Kiinamyllynkatu 4-8, 20521 Turku, Finland
| | - Pauliina Luoto
- Turku PET Centre, Turku University Hospital, University of Turku, Kiinamyllynkatu 4-8, 20521 Turku, Finland
| | - Jukka Kemppainen
- Turku PET Centre, Turku University Hospital, University of Turku, Kiinamyllynkatu 4-8, 20521 Turku, Finland
| | - Anne Roivainen
- Turku PET Centre, Turku University Hospital, University of Turku, Kiinamyllynkatu 4-8, 20521 Turku, Finland ; Turku Center for Disease Modeling, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland
| | - Heikki Minn
- Department of Oncology and Radiotherapy, Turku University Hospital, Hämeentie 11, 20521 Turku, Finland
| |
Collapse
|
1390
|
Morgan LL. The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol 2015; 17:623-4. [PMID: 25605816 PMCID: PMC4483082 DOI: 10.1093/neuonc/nou358] [Citation(s) in RCA: 84] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2014] [Accepted: 12/14/2014] [Indexed: 01/09/2023] Open
|
1391
|
Dong X, Deng Q, Nie X, Zhang M, Jia W, Chen C, Xu C, Xu R. Downregulation of HTATIP2 expression is associated with promoter methylation and poor prognosis in glioma. Exp Mol Pathol 2015; 98:192-9. [DOI: 10.1016/j.yexmp.2015.01.013] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2014] [Revised: 12/17/2014] [Accepted: 01/07/2015] [Indexed: 02/05/2023]
|
1392
|
Dali-Youcef N, Froelich S, Moussallieh FM, Chibbaro S, Noël G, Namer IJ, Heikkinen S, Auwerx J. Gene expression mapping of histone deacetylases and co-factors, and correlation with survival time and 1H-HRMAS metabolomic profile in human gliomas. Sci Rep 2015; 5:9087. [PMID: 25791281 PMCID: PMC4367156 DOI: 10.1038/srep09087] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2014] [Accepted: 02/19/2015] [Indexed: 01/12/2023] Open
Abstract
Primary brain tumors are presently classified based on imaging and histopathological
techniques, which remains unsatisfaying. We profiled here by quantitative real time
PCR (qRT-PCR) the transcripts of eighteen histone deacetylases (HDACs) and a subset
of transcriptional co-factors in non-tumoral brain samples from 15 patients operated
for epilepsia and in brain tumor samples from 50 patients diagnosed with grade II
oligodendrogliomas (ODII, n = 9), grade III oligodendrogliomas (ODIII, n = 22) and
glioblastomas (GL, n = 19). Co-factor transcripts were significantly different in
tumors as compared to non-tumoral samples and distinguished different molecular
subgroups of brain tumors, regardless of tumor grade. Among all patients studied,
the expression of HDAC1 and HDAC3 was inversely correlated with
survival, whereas the expression of HDAC4, HDAC5, HDAC6,
HDAC11 and SIRT1 was significantly and positively correlated with
survival time of patients with gliomas. 1H-HRMAS technology revealed
metabolomically distinct groups according to the expression of HDAC1, HDAC4 and
SIRT1, suggesting that these genes may play an important role in regulating brain
tumorigenesis and cancer progression. Our study hence identified different molecular
fingerprints for subgroups of histopathologically similar brain tumors that may
enable the prediction of outcome based on the expression level of co-factor genes
and could allow customization of treatment.
Collapse
Affiliation(s)
- Nassim Dali-Youcef
- 1] Laboratoire de Biochimie et Biologie Moléculaire, Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil, 1 place de l'hôpital, 67091 Strasbourg Cedex, France [2] Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC)/CNRS UMR 7104/INSERM U 964/Université de Strasbourg, 1 rue Laurent Fries, 67404 Illkirch, France
| | - Sébastien Froelich
- Department of Neurosurgery, Hôpitaux Universitaires de Strasbourg, avenue Molière, 67085 Strasbourg Cedex, France
| | - François-Marie Moussallieh
- Department of Biophysics and Nuclear Medicine, Hôpitaux Universitaires de Strasbourg, CHU de Hautepierre, avenue Molière, 67200 Strasbourg Cedex, France
| | - Salvatore Chibbaro
- Department of Neurosurgery, Hôpitaux Universitaires de Strasbourg, avenue Molière, 67085 Strasbourg Cedex, France
| | - Georges Noël
- Centre Paul Strauss, 3 rue de la porte de l'Hôpital 67065 Strasbourg, Cedex, France
| | - Izzie J Namer
- Department of Biophysics and Nuclear Medicine, Hôpitaux Universitaires de Strasbourg, CHU de Hautepierre, avenue Molière, 67200 Strasbourg Cedex, France
| | - Sami Heikkinen
- Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC)/CNRS UMR 7104/INSERM U 964/Université de Strasbourg, 1 rue Laurent Fries, 67404 Illkirch, France
| | - Johan Auwerx
- 1] Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC)/CNRS UMR 7104/INSERM U 964/Université de Strasbourg, 1 rue Laurent Fries, 67404 Illkirch, France [2] Institut Clinique de la Souris, 1 rue Laurent Fries, 67404 Illkirch, France
| |
Collapse
|
1393
|
Cognitive strategies and quality of life of patients with high-grade glioma. Support Care Cancer 2015; 23:3427-35. [PMID: 25761757 DOI: 10.1007/s00520-015-2691-z] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2014] [Accepted: 03/02/2015] [Indexed: 12/13/2022]
Abstract
The purpose of this study was to analyze the psychological well-being, quality of life, and cognitive strategies activated by patients with high-grade glioma. We hypothesized that the self-perceived quality of life is modulated by physical and psychological factors and that in order to understand this modulation more psychometric approaches are necessary. Data were collected from a sample of 73 consecutive patients with a histological diagnosis of primary malignant brain cancer (grade IV glioblastoma and grade III anaplastic astrocytoma) hospitalized in a specialized Italian center. The Functional Assessment of Cancer Therapy (FACT) scale and the Schedule of Evaluation of Individual Quality of Life-Direct Weighting (SEIQoL-DW) scale were used to assess quality of life. The mean FACT-Brain (Br) score was 122.37. Similarly, the median SEIQoL-DW score was 72.9 out of a maximum value of 100. No gender effect was found in relation to overall quality of life. Patients with high depression and/or anxiety scores reported lower quality of life (QoL) scores in all the instruments considered. We did not find any gender effect concerning depression and anxiety levels. However, we found that men and women, though having similar physical and functional well-being, reported different QoL determinants, since men seem to rely more on physical adjustment, while women activate more introspective strategies. Positive actions, family issues, negative thoughts, health, and positive thoughts were found to be the most reported themes. In conclusion, the present study strongly suggests that a positive psychological adjustment is possible also in the event of a severe diagnosis and during aggressive treatments, but QoL determinants might be considered too in order to help health professionals to understand patients' experience and to meet their needs.
Collapse
|
1394
|
Neagu MR, Huang RY, Reardon DA, Wen PY. How treatment monitoring is influencing treatment decisions in glioblastomas. Curr Treat Options Neurol 2015; 17:343. [PMID: 25749847 DOI: 10.1007/s11940-015-0343-8] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
OPINION STATEMENT Glioblastoma (GBM), the most common malignant primary tumor in adults, carries a dismal prognosis with an average median survival of 14-16 months. The current standard of care for newly diagnosed GBM consists of maximal safe resection followed by fractionated radiotherapy combined with concurrent temozolomide and 6 to 12 cycles of adjuvant temozolomide. The determination of treatment response and clinical decision-making in the treatment of GBM depends on accurate radiographic assessment. Differentiating treatment response from tumor progression is challenging and combines long-term follow-up using standard MRI, with assessing clinical status and corticosteroid dependency. At progression, bevacizumab is the mainstay of treatment. Incorporation of antiangiogenic therapies leads to rapid blood-brain barrier normalization with remarkable radiographic response often not accompanied by the expected survival benefit, further complicating imaging assessment. Improved radiographic interpretation criteria, such as the Response Assessment in Neuro-Oncology (RANO) criteria, incorporate non-enhancing disease but still fall short of definitely distinguishing tumor progression, pseudoresponse, and pseudoprogression. With new evolving treatment modalities for this devastating disease, advanced imaging modalities are increasingly becoming part of routine clinical care in a field where neuroimaging has such essential role in guiding treatment decisions and defining clinical trial eligibility and efficacy.
Collapse
Affiliation(s)
- Martha R Neagu
- Dana Farber Cancer Institute, G4200, 44 Binney St, Boston, MA, 02115, USA
| | | | | | | |
Collapse
|
1395
|
Ma Y, Qu B, Xia X, Yang L, Kuang Y, Yang T, Cheng J, Sun H, Fan K, Gu J. Glioma-Derived Thrombospondin-1 Modulates Cd14+ Cell Tolerogenic Properties. Cancer Invest 2015; 33:152-7. [DOI: 10.3109/07357907.2015.1010089] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
1396
|
Lloyd RE, Keatley K, Littlewood DTJ, Meunier B, Holt WV, An Q, Higgins SC, Polyzoidis S, Stephenson KF, Ashkan K, Fillmore HL, Pilkington GJ, McGeehan JE. Identification and functional prediction of mitochondrial complex III and IV mutations associated with glioblastoma. Neuro Oncol 2015; 17:942-52. [PMID: 25731774 PMCID: PMC4474231 DOI: 10.1093/neuonc/nov020] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2014] [Accepted: 01/23/2015] [Indexed: 12/30/2022] Open
Abstract
Background Glioblastoma (GBM) is the most common primary brain tumor in adults, with a dismal prognosis. Treatment is hampered by GBM's unique biology, including differential cell response to therapy. Although several mitochondrial abnormalities have been identified, how mitochondrial DNA (mtDNA) mutations contribute to GBM biology and therapeutic response remains poorly described. We sought to determine the spectrum of functional complex III and IV mtDNA mutations in GBM. Methods The complete mitochondrial genomes of 10 GBM cell lines were obtained using next-generation sequencing and combined with another set obtained from 32 GBM tissues. Three-dimensional structural mapping and analysis of all the nonsynonymous mutations identified in complex III and IV proteins was then performed to investigate functional importance. Results Over 200 mutations were identified in the mtDNAs, including a significant proportion with very low mutational loads. Twenty-five were nonsynonymous mutations in complex III and IV, 9 of which were predicted to be functional and affect mitochondrial respiratory chain activity. Most of the functional candidates were GBM specific and not found in the general population, and 2 were present in the germ-line. Patient-specific maps reveal that 43% of tumors carry at least one functional candidate. Conclusions We reveal that the spectrum of GBM-associated mtDNA mutations is wider than previously thought, as well as novel structural-functional links between specific mtDNA mutations, abnormal mitochondria, and the biology of GBM. These results could provide tangible new prognostic indicators as well as targets with which to guide the development of patient-specific mitochondrially mediated chemotherapeutic approaches.
Collapse
Affiliation(s)
- Rhiannon E Lloyd
- Brain Tumour Research Centre (R.E.L., K.K., S.C.H., K.F.S., H.L.F., G.J.P.), Molecular Biophysics Laboratories (K.K., J.E.M.), Epigenetics and Developmental Biology Laboratories (Q.A.), Institute of Biomedical and Biomolecular Sciences, University of Portsmouth, Portsmouth, UK; Department of Life Sciences, Natural History Museum, London, UK (D.T.J.L.); Institut de Biologie Intégrative de la Cellule, Paris-Saclay University, CEA, CNRS, Université Paris-Sud, Gif sur Yvette, France (B.M.); Academic Unit of Reproductive and Developmental Medicine, University of Sheffield, Sheffield, UK (W.V.H.); Department of Neurosurgery, Kings College Hospital, London, UK (S.P., K.A.)
| | - Kathleen Keatley
- Brain Tumour Research Centre (R.E.L., K.K., S.C.H., K.F.S., H.L.F., G.J.P.), Molecular Biophysics Laboratories (K.K., J.E.M.), Epigenetics and Developmental Biology Laboratories (Q.A.), Institute of Biomedical and Biomolecular Sciences, University of Portsmouth, Portsmouth, UK; Department of Life Sciences, Natural History Museum, London, UK (D.T.J.L.); Institut de Biologie Intégrative de la Cellule, Paris-Saclay University, CEA, CNRS, Université Paris-Sud, Gif sur Yvette, France (B.M.); Academic Unit of Reproductive and Developmental Medicine, University of Sheffield, Sheffield, UK (W.V.H.); Department of Neurosurgery, Kings College Hospital, London, UK (S.P., K.A.)
| | - D Timothy J Littlewood
- Brain Tumour Research Centre (R.E.L., K.K., S.C.H., K.F.S., H.L.F., G.J.P.), Molecular Biophysics Laboratories (K.K., J.E.M.), Epigenetics and Developmental Biology Laboratories (Q.A.), Institute of Biomedical and Biomolecular Sciences, University of Portsmouth, Portsmouth, UK; Department of Life Sciences, Natural History Museum, London, UK (D.T.J.L.); Institut de Biologie Intégrative de la Cellule, Paris-Saclay University, CEA, CNRS, Université Paris-Sud, Gif sur Yvette, France (B.M.); Academic Unit of Reproductive and Developmental Medicine, University of Sheffield, Sheffield, UK (W.V.H.); Department of Neurosurgery, Kings College Hospital, London, UK (S.P., K.A.)
| | - Brigitte Meunier
- Brain Tumour Research Centre (R.E.L., K.K., S.C.H., K.F.S., H.L.F., G.J.P.), Molecular Biophysics Laboratories (K.K., J.E.M.), Epigenetics and Developmental Biology Laboratories (Q.A.), Institute of Biomedical and Biomolecular Sciences, University of Portsmouth, Portsmouth, UK; Department of Life Sciences, Natural History Museum, London, UK (D.T.J.L.); Institut de Biologie Intégrative de la Cellule, Paris-Saclay University, CEA, CNRS, Université Paris-Sud, Gif sur Yvette, France (B.M.); Academic Unit of Reproductive and Developmental Medicine, University of Sheffield, Sheffield, UK (W.V.H.); Department of Neurosurgery, Kings College Hospital, London, UK (S.P., K.A.)
| | - William V Holt
- Brain Tumour Research Centre (R.E.L., K.K., S.C.H., K.F.S., H.L.F., G.J.P.), Molecular Biophysics Laboratories (K.K., J.E.M.), Epigenetics and Developmental Biology Laboratories (Q.A.), Institute of Biomedical and Biomolecular Sciences, University of Portsmouth, Portsmouth, UK; Department of Life Sciences, Natural History Museum, London, UK (D.T.J.L.); Institut de Biologie Intégrative de la Cellule, Paris-Saclay University, CEA, CNRS, Université Paris-Sud, Gif sur Yvette, France (B.M.); Academic Unit of Reproductive and Developmental Medicine, University of Sheffield, Sheffield, UK (W.V.H.); Department of Neurosurgery, Kings College Hospital, London, UK (S.P., K.A.)
| | - Qian An
- Brain Tumour Research Centre (R.E.L., K.K., S.C.H., K.F.S., H.L.F., G.J.P.), Molecular Biophysics Laboratories (K.K., J.E.M.), Epigenetics and Developmental Biology Laboratories (Q.A.), Institute of Biomedical and Biomolecular Sciences, University of Portsmouth, Portsmouth, UK; Department of Life Sciences, Natural History Museum, London, UK (D.T.J.L.); Institut de Biologie Intégrative de la Cellule, Paris-Saclay University, CEA, CNRS, Université Paris-Sud, Gif sur Yvette, France (B.M.); Academic Unit of Reproductive and Developmental Medicine, University of Sheffield, Sheffield, UK (W.V.H.); Department of Neurosurgery, Kings College Hospital, London, UK (S.P., K.A.)
| | - Samantha C Higgins
- Brain Tumour Research Centre (R.E.L., K.K., S.C.H., K.F.S., H.L.F., G.J.P.), Molecular Biophysics Laboratories (K.K., J.E.M.), Epigenetics and Developmental Biology Laboratories (Q.A.), Institute of Biomedical and Biomolecular Sciences, University of Portsmouth, Portsmouth, UK; Department of Life Sciences, Natural History Museum, London, UK (D.T.J.L.); Institut de Biologie Intégrative de la Cellule, Paris-Saclay University, CEA, CNRS, Université Paris-Sud, Gif sur Yvette, France (B.M.); Academic Unit of Reproductive and Developmental Medicine, University of Sheffield, Sheffield, UK (W.V.H.); Department of Neurosurgery, Kings College Hospital, London, UK (S.P., K.A.)
| | - Stavros Polyzoidis
- Brain Tumour Research Centre (R.E.L., K.K., S.C.H., K.F.S., H.L.F., G.J.P.), Molecular Biophysics Laboratories (K.K., J.E.M.), Epigenetics and Developmental Biology Laboratories (Q.A.), Institute of Biomedical and Biomolecular Sciences, University of Portsmouth, Portsmouth, UK; Department of Life Sciences, Natural History Museum, London, UK (D.T.J.L.); Institut de Biologie Intégrative de la Cellule, Paris-Saclay University, CEA, CNRS, Université Paris-Sud, Gif sur Yvette, France (B.M.); Academic Unit of Reproductive and Developmental Medicine, University of Sheffield, Sheffield, UK (W.V.H.); Department of Neurosurgery, Kings College Hospital, London, UK (S.P., K.A.)
| | - Katie F Stephenson
- Brain Tumour Research Centre (R.E.L., K.K., S.C.H., K.F.S., H.L.F., G.J.P.), Molecular Biophysics Laboratories (K.K., J.E.M.), Epigenetics and Developmental Biology Laboratories (Q.A.), Institute of Biomedical and Biomolecular Sciences, University of Portsmouth, Portsmouth, UK; Department of Life Sciences, Natural History Museum, London, UK (D.T.J.L.); Institut de Biologie Intégrative de la Cellule, Paris-Saclay University, CEA, CNRS, Université Paris-Sud, Gif sur Yvette, France (B.M.); Academic Unit of Reproductive and Developmental Medicine, University of Sheffield, Sheffield, UK (W.V.H.); Department of Neurosurgery, Kings College Hospital, London, UK (S.P., K.A.)
| | - Keyoumars Ashkan
- Brain Tumour Research Centre (R.E.L., K.K., S.C.H., K.F.S., H.L.F., G.J.P.), Molecular Biophysics Laboratories (K.K., J.E.M.), Epigenetics and Developmental Biology Laboratories (Q.A.), Institute of Biomedical and Biomolecular Sciences, University of Portsmouth, Portsmouth, UK; Department of Life Sciences, Natural History Museum, London, UK (D.T.J.L.); Institut de Biologie Intégrative de la Cellule, Paris-Saclay University, CEA, CNRS, Université Paris-Sud, Gif sur Yvette, France (B.M.); Academic Unit of Reproductive and Developmental Medicine, University of Sheffield, Sheffield, UK (W.V.H.); Department of Neurosurgery, Kings College Hospital, London, UK (S.P., K.A.)
| | - Helen L Fillmore
- Brain Tumour Research Centre (R.E.L., K.K., S.C.H., K.F.S., H.L.F., G.J.P.), Molecular Biophysics Laboratories (K.K., J.E.M.), Epigenetics and Developmental Biology Laboratories (Q.A.), Institute of Biomedical and Biomolecular Sciences, University of Portsmouth, Portsmouth, UK; Department of Life Sciences, Natural History Museum, London, UK (D.T.J.L.); Institut de Biologie Intégrative de la Cellule, Paris-Saclay University, CEA, CNRS, Université Paris-Sud, Gif sur Yvette, France (B.M.); Academic Unit of Reproductive and Developmental Medicine, University of Sheffield, Sheffield, UK (W.V.H.); Department of Neurosurgery, Kings College Hospital, London, UK (S.P., K.A.)
| | - Geoffrey J Pilkington
- Brain Tumour Research Centre (R.E.L., K.K., S.C.H., K.F.S., H.L.F., G.J.P.), Molecular Biophysics Laboratories (K.K., J.E.M.), Epigenetics and Developmental Biology Laboratories (Q.A.), Institute of Biomedical and Biomolecular Sciences, University of Portsmouth, Portsmouth, UK; Department of Life Sciences, Natural History Museum, London, UK (D.T.J.L.); Institut de Biologie Intégrative de la Cellule, Paris-Saclay University, CEA, CNRS, Université Paris-Sud, Gif sur Yvette, France (B.M.); Academic Unit of Reproductive and Developmental Medicine, University of Sheffield, Sheffield, UK (W.V.H.); Department of Neurosurgery, Kings College Hospital, London, UK (S.P., K.A.)
| | - John E McGeehan
- Brain Tumour Research Centre (R.E.L., K.K., S.C.H., K.F.S., H.L.F., G.J.P.), Molecular Biophysics Laboratories (K.K., J.E.M.), Epigenetics and Developmental Biology Laboratories (Q.A.), Institute of Biomedical and Biomolecular Sciences, University of Portsmouth, Portsmouth, UK; Department of Life Sciences, Natural History Museum, London, UK (D.T.J.L.); Institut de Biologie Intégrative de la Cellule, Paris-Saclay University, CEA, CNRS, Université Paris-Sud, Gif sur Yvette, France (B.M.); Academic Unit of Reproductive and Developmental Medicine, University of Sheffield, Sheffield, UK (W.V.H.); Department of Neurosurgery, Kings College Hospital, London, UK (S.P., K.A.)
| |
Collapse
|
1397
|
Chen Y, Wu Y, Huang X, Qu P, Li G, Jin T, Xing J, He S. Leukocyte telomere length: a novel biomarker to predict the prognosis of glioma patients. J Cancer Res Clin Oncol 2015; 141:1739-47. [PMID: 25702101 DOI: 10.1007/s00432-015-1938-x] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2015] [Accepted: 02/12/2015] [Indexed: 10/24/2022]
Abstract
PURPOSE Epidemiological studies have demonstrated that leukocyte telomere length is associated with the developing risk of various malignancies, including glioma. However, its prognostic value in glioma patients has never been investigated. METHODS Relative telomere length (RTL) of peripheral blood leukocytes from 301 glioma patients were examined using a real-time PCR-based method. Kaplan-Meier curves and Cox proportional hazards regression model were used to assess the association of RTL with clinical outcomes of patients. To explore the potential mechanism, the immune phenotype of peripheral blood mononuclear cells (PBMCs) and concentrations of several cytokines from another 20 glioma patients were detected by flow cytometry and enzyme-linked immunosorbent assay (ELISA), respectively. The relationship between RTL and immunological characteristics of PBMCs were further analyzed. RESULTS Patients with short RTL showed both poorer overall survival (OS) and progression-free survival (PFS) than those with long RTL. Multivariate Cox regression analysis demonstrated that RTL was an independent prognostic factor for both OS and PFS in glioma patients. Moreover, the effects of RTL on the prognosis of patients exhibited a dose-dependent manner. Stratified analysis showed that the prognostic value of RTL was not affected by host characteristics except for age. In addition, flow cytometry and ELISA analyses indicated that there was no significant association between RTL and frequency of different immune cell subsets or plasma cytokine concentrations. CONCLUSIONS Our study for the first time demonstrates that leukocyte RTL is an independent prognostic marker for glioma patients. The potential mechanism needs further investigation.
Collapse
Affiliation(s)
- Yibing Chen
- State Key Laboratory of Cancer Biology and Experimental Teaching Center of Basic Medicine, Fourth Military Medical University, 169 Changle West Road, Xi'an, 710032, Shaanxi, China
| | | | | | | | | | | | | | | |
Collapse
|
1398
|
Liu X, Lei Q, Yu Z, Xu G, Tang H, Wang W, Wang Z, Li G, Wu M. MiR-101 reverses the hypomethylation of the LMO3 promoter in glioma cells. Oncotarget 2015; 6:7930-43. [PMID: 25829251 PMCID: PMC4480726 DOI: 10.18632/oncotarget.3181] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2014] [Accepted: 01/23/2015] [Indexed: 01/09/2023] Open
Abstract
LIM-only protein 3 (LMO3), a member of the LIM-only protein group, is a new DNA methylation gene that was identified in gliomas via the MeDIP-Chip in our previous study. In this study, we found that LIM-only protein 3 (LMO3) is hypomethylated and overexpressed in glioma cells and tissues. The overexpression of LMO3 was correlated with a poor prognosis in glioma patients, and LMO3 was indirectly inhibited by the tumor suppressor miR-101, which is a potential prognosis marker of gliomas. MiR-101 decreased the expression of LMO3 by reversing the methylation status of the LMO3 promoter and by inhibiting the presence of the methylation-related histones H3K4me2 and H3K27me3 and increasing the presence of H3K9me3 and H4K20me3 on the promoter. It was determined that miR-101 decreases the occupancy of H3K27me3 by inhibiting EZH2, DNMT3A and EED and decreases the H3K9me3 occupancy on the LMO3 promoter via SUV39H1, SUV39H2, G9a and PHF8. Furthermore, miR-101 suppresses the expression of LMO3 by decreasing USF and MZF1.
Collapse
Affiliation(s)
- Xiaoping Liu
- 1 Hunan Provincial Tumor Hospital and the Affiliated Tumor Hospital of Xiangya Medical School, Central South University, Changsha 410013, Hunan, China,2 Department of Breast Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, Guangdong, China
| | - Qianqian Lei
- 1 Hunan Provincial Tumor Hospital and the Affiliated Tumor Hospital of Xiangya Medical School, Central South University, Changsha 410013, Hunan, China
| | - Zhibin Yu
- 1 Hunan Provincial Tumor Hospital and the Affiliated Tumor Hospital of Xiangya Medical School, Central South University, Changsha 410013, Hunan, China
| | - Gang Xu
- 1 Hunan Provincial Tumor Hospital and the Affiliated Tumor Hospital of Xiangya Medical School, Central South University, Changsha 410013, Hunan, China,4 Medical College, University of South China, Hengyang 421001, Hunan, China
| | - Hailin Tang
- 2 Department of Breast Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, Guangdong, China
| | - Wei Wang
- 1 Hunan Provincial Tumor Hospital and the Affiliated Tumor Hospital of Xiangya Medical School, Central South University, Changsha 410013, Hunan, China
| | - Zeyou Wang
- 1 Hunan Provincial Tumor Hospital and the Affiliated Tumor Hospital of Xiangya Medical School, Central South University, Changsha 410013, Hunan, China
| | - Guiyuan Li
- 1 Hunan Provincial Tumor Hospital and the Affiliated Tumor Hospital of Xiangya Medical School, Central South University, Changsha 410013, Hunan, China,3 School of Basic Medical Science, Cancer Research Institute, Central South University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Key Laboratory of Carcinogenesis, Ministry of Health, Changsha 410078, Hunan, China
| | - Minghua Wu
- 1 Hunan Provincial Tumor Hospital and the Affiliated Tumor Hospital of Xiangya Medical School, Central South University, Changsha 410013, Hunan, China,3 School of Basic Medical Science, Cancer Research Institute, Central South University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Key Laboratory of Carcinogenesis, Ministry of Health, Changsha 410078, Hunan, China
| |
Collapse
|
1399
|
Abstract
Gliomas are the most common type of primary intracranial tumors. Some glioma subtypes cause significant mortality and morbidity that are disproportionate to their relatively rare incidence. A very small proportion of glioma cases can be attributed to inherited genetic disorders. Many potential risk factors for glioma have been studied to date, but few provide explanation for the number of brain tumors identified. The most significant of these factors includes increased risk due to exposure to ionizing radiation, and decreased risk with history of allergy or atopic disease. The potential effect of exposure to cellular phones has been studied extensively, but the results remain inconclusive. Recent genomic analyses, using the genome-wide association study (GWAS) design, have identified several inherited risk variants that are associated with increased glioma risk. The following chapter provides an overview of the current state of research in the epidemiology of intracranial glioma.
Collapse
|
1400
|
Jalali A, Amirian ES, Bainbridge MN, Armstrong GN, Liu Y, Tsavachidis S, Jhangiani SN, Plon SE, Lau CC, Claus EB, Barnholtz-Sloan JS, Il'yasova D, Schildkraut J, Ali-Osman F, Sadetzki S, Johansen C, Houlston RS, Jenkins RB, Lachance D, Olson SH, Bernstein JL, Merrell RT, Wrensch MR, Davis FG, Lai R, Shete S, Aldape K, Amos CI, Muzny DM, Gibbs RA, Melin BS, Bondy ML. Targeted sequencing in chromosome 17q linkage region identifies familial glioma candidates in the Gliogene Consortium. Sci Rep 2015; 5:8278. [PMID: 25652157 PMCID: PMC4317686 DOI: 10.1038/srep08278] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2014] [Accepted: 01/06/2015] [Indexed: 12/30/2022] Open
Abstract
Glioma is a rare, but highly fatal, cancer that accounts for the majority of malignant primary brain tumors. Inherited predisposition to glioma has been consistently observed within non-syndromic families. Our previous studies, which involved non-parametric and parametric linkage analyses, both yielded significant linkage peaks on chromosome 17q. Here, we use data from next generation and Sanger sequencing to identify familial glioma candidate genes and variants on chromosome 17q for further investigation. We applied a filtering schema to narrow the original list of 4830 annotated variants down to 21 very rare (<0.1% frequency), non-synonymous variants. Our findings implicate the MYO19 and KIF18B genes and rare variants in SPAG9 and RUNDC1 as candidates worthy of further investigation. Burden testing and functional studies are planned.
Collapse
Affiliation(s)
- Ali Jalali
- Department of Neurosurgery, Baylor College of Medicine, Houston, Texas
| | - E. Susan Amirian
- Department of Pediatrics, Division of Hematology-Oncology, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas
| | - Matthew N. Bainbridge
- Codified Genomics, LLC, Houston Texas
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas
| | - Georgina N. Armstrong
- Department of Pediatrics, Division of Hematology-Oncology, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas
| | - Yanhong Liu
- Department of Pediatrics, Division of Hematology-Oncology, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas
| | - Spyros Tsavachidis
- Department of Pediatrics, Division of Hematology-Oncology, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas
| | | | - Sharon E. Plon
- Department of Pediatrics, Division of Hematology-Oncology, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas
| | - Ching C. Lau
- Department of Pediatrics, Division of Hematology-Oncology, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas
| | - Elizabeth B. Claus
- Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut
- Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts
| | - Jill S. Barnholtz-Sloan
- Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Dora Il'yasova
- Department of Epidemiology and Biostatistics, Georgia State University School of Public Health, Atlanta, Georgia
- Cancer Control and Prevention Program, Department of Community and Family Medicine, Duke University Medical Center, Durham, North Carolina
| | - Joellen Schildkraut
- Cancer Control and Prevention Program, Department of Community and Family Medicine, Duke University Medical Center, Durham, North Carolina
| | - Francis Ali-Osman
- Department of Surgery, Duke University Medical Center, Durham, North Carolina
| | - Siegal Sadetzki
- Cancer and Radiation Epidemiology Unit, Gertner Institute, Chaim Sheba Medical Center, Tel Hashomer
- Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Christoffer Johansen
- Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark
- Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - Richard S. Houlston
- Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, United Kingdom
| | - Robert B. Jenkins
- Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, Minnesota
| | - Daniel Lachance
- Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, Minnesota
| | - Sara H. Olson
- Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Jonine L. Bernstein
- Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Ryan T. Merrell
- Department of Neurology, NorthShore University HealthSystem, Evanston, Illinois
| | - Margaret R. Wrensch
- Department of Neurological Surgery, University of California, San Francisco, San Francisco, California
| | - Faith G. Davis
- Department of Public Health Services, University of Alberta, Edmonton, Alberta, Canada
| | - Rose Lai
- Departments of Neurology, Neurosurgery, and Preventive Medicine, The University of Southern California Keck School of Medicine, Los Angeles, California
| | - Sanjay Shete
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Kenneth Aldape
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Christopher I. Amos
- Department of Community and Family Medicine, Department of Genetics, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth; Hanover, New Hampshire
| | - Donna M. Muzny
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas
| | - Richard A. Gibbs
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas
| | - Beatrice S. Melin
- Department of Radiation Sciences Oncology, Umeå University, Umeå, Sweden
| | - Melissa L. Bondy
- Department of Pediatrics, Division of Hematology-Oncology, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas
| |
Collapse
|